0000875320-22-000038.txt : 20221028 0000875320-22-000038.hdr.sgml : 20221028 20221028160751 ACCESSION NUMBER: 0000875320-22-000038 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221028 DATE AS OF CHANGE: 20221028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 221341911 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 vrtx-20220930.htm 10-Q vrtx-20220930
VERTEX PHARMACEUTICALS INC / MA000087532012/312022Q3falseP1M00008753202022-01-012022-09-3000008753202022-10-21xbrli:shares0000875320us-gaap:ProductMember2022-07-012022-09-30iso4217:USD0000875320us-gaap:ProductMember2021-07-012021-09-300000875320us-gaap:ProductMember2022-01-012022-09-300000875320us-gaap:ProductMember2021-01-012021-09-300000875320vrtx:CollaborativeandRoyaltyMember2022-07-012022-09-300000875320vrtx:CollaborativeandRoyaltyMember2021-07-012021-09-300000875320vrtx:CollaborativeandRoyaltyMember2022-01-012022-09-300000875320vrtx:CollaborativeandRoyaltyMember2021-01-012021-09-3000008753202022-07-012022-09-3000008753202021-07-012021-09-3000008753202021-01-012021-09-30iso4217:USDxbrli:shares00008753202022-09-3000008753202021-12-310000875320us-gaap:CommonStockMember2021-06-300000875320us-gaap:AdditionalPaidInCapitalMember2021-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000875320us-gaap:RetainedEarningsMember2021-06-3000008753202021-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000875320us-gaap:RetainedEarningsMember2021-07-012021-09-300000875320us-gaap:CommonStockMember2021-07-012021-09-300000875320us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000875320us-gaap:CommonStockMember2021-09-300000875320us-gaap:AdditionalPaidInCapitalMember2021-09-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000875320us-gaap:RetainedEarningsMember2021-09-3000008753202021-09-300000875320us-gaap:CommonStockMember2022-06-300000875320us-gaap:AdditionalPaidInCapitalMember2022-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000875320us-gaap:RetainedEarningsMember2022-06-3000008753202022-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000875320us-gaap:RetainedEarningsMember2022-07-012022-09-300000875320us-gaap:CommonStockMember2022-07-012022-09-300000875320us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000875320us-gaap:CommonStockMember2022-09-300000875320us-gaap:AdditionalPaidInCapitalMember2022-09-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000875320us-gaap:RetainedEarningsMember2022-09-300000875320us-gaap:CommonStockMember2020-12-310000875320us-gaap:AdditionalPaidInCapitalMember2020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000875320us-gaap:RetainedEarningsMember2020-12-3100008753202020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000875320us-gaap:RetainedEarningsMember2021-01-012021-09-300000875320us-gaap:CommonStockMember2021-01-012021-09-300000875320us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000875320us-gaap:CommonStockMember2021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000875320us-gaap:RetainedEarningsMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000875320us-gaap:RetainedEarningsMember2022-01-012022-09-300000875320us-gaap:CommonStockMember2022-01-012022-09-300000875320us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-30vrtx:segment0000875320vrtx:TRIKAFTAKAFTRIOMember2022-07-012022-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2021-07-012021-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2022-01-012022-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2021-01-012021-09-300000875320vrtx:SYMDEKOSYMKEVIMember2022-07-012022-09-300000875320vrtx:SYMDEKOSYMKEVIMember2021-07-012021-09-300000875320vrtx:SYMDEKOSYMKEVIMember2022-01-012022-09-300000875320vrtx:SYMDEKOSYMKEVIMember2021-01-012021-09-300000875320vrtx:ORKAMBIMember2022-07-012022-09-300000875320vrtx:ORKAMBIMember2021-07-012021-09-300000875320vrtx:ORKAMBIMember2022-01-012022-09-300000875320vrtx:ORKAMBIMember2021-01-012021-09-300000875320vrtx:KalydecoMember2022-07-012022-09-300000875320vrtx:KalydecoMember2021-07-012021-09-300000875320vrtx:KalydecoMember2022-01-012022-09-300000875320vrtx:KalydecoMember2021-01-012021-09-300000875320country:US2022-07-012022-09-300000875320country:US2021-07-012021-09-300000875320country:US2022-01-012022-09-300000875320country:US2021-01-012021-09-300000875320srt:EuropeMember2022-07-012022-09-300000875320srt:EuropeMember2021-07-012021-09-300000875320srt:EuropeMember2022-01-012022-09-300000875320srt:EuropeMember2021-01-012021-09-300000875320vrtx:OtherNonU.S.Member2022-07-012022-09-300000875320vrtx:OtherNonU.S.Member2021-07-012021-09-300000875320vrtx:OtherNonU.S.Member2022-01-012022-09-300000875320vrtx:OtherNonU.S.Member2021-01-012021-09-300000875320us-gaap:NonUsMember2022-07-012022-09-300000875320us-gaap:NonUsMember2021-07-012021-09-300000875320us-gaap:NonUsMember2022-01-012022-09-300000875320us-gaap:NonUsMember2021-01-012021-09-300000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-31vrtx:target0000875320vrtx:CRSIPRARJDCAMember2021-04-012021-06-300000875320vrtx:CRSIPRARJDCAMember2021-07-01xbrli:pure0000875320vrtx:CRISPRMembervrtx:CRSIPRARJDCAMember2021-07-010000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2022-07-012022-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2021-07-012021-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2022-01-012022-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2021-01-012021-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMember2022-07-012022-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMember2021-07-012021-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMember2022-01-012022-09-300000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMember2021-01-012021-09-300000875320vrtx:VerveMember2022-07-012022-07-310000875320vrtx:CatalystBiosciencesMember2022-05-012022-05-310000875320vrtx:ViaCyteMember2022-09-272022-09-270000875320vrtx:ViaCyteMember2022-09-270000875320us-gaap:InProcessResearchAndDevelopmentMembervrtx:ViaCyteMember2022-09-270000875320us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000875320us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000875320us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000875320us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000875320us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000875320us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000875320us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000875320us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:BankTimeDepositsMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:BankTimeDepositsMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000875320us-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:FairValueInputsLevel3Member2022-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2022-09-300000875320srt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-09-300000875320us-gaap:InProcessResearchAndDevelopmentMembervrtx:ViaCyteMember2022-09-300000875320us-gaap:InProcessResearchAndDevelopmentMembervrtx:ViaCyteMember2021-12-310000875320us-gaap:InProcessResearchAndDevelopmentMembervrtx:ViaCyteMember2022-07-012022-09-300000875320us-gaap:InProcessResearchAndDevelopmentMembervrtx:ViaCyteMember2022-01-012022-09-300000875320us-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2022-09-300000875320us-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:CashAndCashEquivalentsMemberus-gaap:BankTimeDepositsMember2022-09-300000875320us-gaap:CashAndCashEquivalentsMemberus-gaap:BankTimeDepositsMember2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:CashAndCashEquivalentsMember2022-09-300000875320us-gaap:CommercialPaperMemberus-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:CashAndCashEquivalentsMember2022-09-300000875320us-gaap:CashAndCashEquivalentsMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USTreasurySecuritiesMember2022-09-300000875320vrtx:MarketableSecuritiesMemberus-gaap:USTreasurySecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-09-300000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2022-09-300000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMembervrtx:MarketableSecuritiesMember2022-09-300000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMembervrtx:MarketableSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMember2022-09-300000875320vrtx:MarketableSecuritiesMember2021-12-3100008753202021-01-012021-12-310000875320us-gaap:OtherAssetsMember2022-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000875320us-gaap:ForeignExchangeForwardMembersrt:MinimumMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300000875320srt:MaximumMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMembercurrency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMembercurrency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMembercurrency:AUDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMembercurrency:AUDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CHFus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CHFus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000875320us-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000875320us-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000875320us-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMember2022-07-012022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMember2021-07-012021-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMember2022-01-012022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMember2021-01-012021-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CashFlowHedgingMember2022-09-300000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CashFlowHedgingMember2021-12-310000875320us-gaap:RestrictedStockMember2022-07-012022-09-300000875320us-gaap:RestrictedStockMember2021-07-012021-09-300000875320us-gaap:RestrictedStockMember2022-01-012022-09-300000875320us-gaap:RestrictedStockMember2021-01-012021-09-300000875320us-gaap:EmployeeStockMember2022-07-012022-09-300000875320us-gaap:EmployeeStockMember2021-07-012021-09-300000875320us-gaap:EmployeeStockMember2022-01-012022-09-300000875320us-gaap:EmployeeStockMember2021-01-012021-09-300000875320us-gaap:CostOfSalesMember2022-07-012022-09-300000875320us-gaap:CostOfSalesMember2021-07-012021-09-300000875320us-gaap:CostOfSalesMember2022-01-012022-09-300000875320us-gaap:CostOfSalesMember2021-01-012021-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000875320vrtx:ShareRepurchaseProgram2020Member2020-11-300000875320vrtx:ShareRepurchaseProgram2020Member2021-01-012021-03-310000875320vrtx:ShareRepurchaseProgram2021Member2021-06-300000875320vrtx:ShareRepurchaseProgram2021Member2022-01-012022-09-300000875320vrtx:ShareRepurchaseProgram2021Member2022-09-300000875320us-gaap:RevolvingCreditFacilityMember2022-07-310000875320us-gaap:LetterOfCreditMember2022-07-310000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2022-07-012022-07-310000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2022-07-012022-07-310000875320us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMember2022-07-012022-07-310000875320srt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMember2019-12-310000875320us-gaap:RevolvingCreditFacilityMember2022-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or organization)

50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)

02210
(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
256,691,452
Outstanding at October 21, 2022

VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2022

TABLE OF CONTENTS
Page
Condensed Consolidated Statements of Operations - Three and Nine Months Ended September 30, 2022 and 2021
Condensed Consolidated Statements of Comprehensive Income - Three and Nine Months Ended September 30, 2022 and 2021
Condensed Consolidated Balance Sheets - September 30, 2022 and December 31, 2021
Condensed Consolidated Statements of Shareholders' Equity - Three and Nine Months Ended September 30, 2022 and 2021
Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2022 and 2021
Item 1A.

“Vertex,” “we,” “us,” and “our” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®,” “TRIKAFTA®” and “KAFTRIO®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.


Part I. Financial Information

Item 1.  Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in millions, except per share amounts)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenues:
Product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Other revenues— — — 1.0 
Total revenues2,334.3 1,984.1 6,628.0 5,501.8 
Costs and expenses:
Cost of sales289.4 236.5 797.0 656.8 
Research and development expenses645.0 467.0 1,846.2 1,370.0 
Acquired in-process research and development expenses29.0 26.7 92.9 986.8 
Selling, general and administrative expenses246.8 198.2 677.3 584.9 
Change in fair value of contingent consideration(2.6)1.2 (59.3)(1.1)
Total costs and expenses1,207.6 929.6 3,354.1 3,597.4 
Income from operations1,126.7 1,054.5 3,273.9 1,904.4 
Interest income46.2 1.1 58.6 3.7 
Interest expense(13.7)(15.2)(43.2)(46.4)
Other income (expense), net17.2 42.4 (133.7)(2.2)
Income before provision for income taxes1,176.4 1,082.8 3,155.6 1,859.5 
Provision for income taxes245.9 230.9 652.5 287.5 
Net income$930.5 $851.9 $2,503.1 $1,572.0 
Net income per common share:
Basic$3.63 $3.30 $9.78 $6.08 
Diluted$3.59 $3.28 $9.68 $6.03 
Shares used in per share calculations:
Basic256.5 257.9 255.8 258.7 
Diluted259.5 259.7 258.7 260.9 
Please refer to Note A, “Basis of Presentation and Accounting Policies,” for an explanation of amounts reclassified from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and nine months ended September 30, 2021.
The accompanying notes are an integral part of these condensed consolidated financial statements.

2
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net income$930.5 $851.9 $2,503.1 $1,572.0 
Other comprehensive income:
Unrealized holding losses on marketable securities, net
(0.6)(0.0)(3.6)(0.3)
Unrealized gains on foreign currency forward contracts, net of tax of $(16.0), $(9.6), $(34.3) and $(21.2), respectively
58.8 34.7 128.1 77.0 
Foreign currency translation adjustment(18.1)2.0 (42.8)3.3 
Total other comprehensive income
40.1 36.7 81.7 80.0 
Comprehensive income$970.6 $888.6 $2,584.8 $1,652.0 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in millions, except share data)
September 30,December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$9,171.5 $6,795.0 
Marketable securities599.2 729.9 
Accounts receivable, net1,385.2 1,136.8 
Inventories388.2 353.1 
Prepaid expenses and other current assets
726.9 545.8 
Total current assets
12,271.0 9,560.6 
Property and equipment, net1,118.7 1,094.1 
Goodwill1,075.2 1,002.2 
Intangible assets
603.6 400.0 
Deferred tax assets
1,162.7 934.5 
Operating lease assets
342.7 330.3 
Other assets
132.5 110.8 
Total assets
$16,706.4 $13,432.5 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$126.9 $195.0 
Accrued expenses2,264.4 1,678.6 
Other current liabilities
218.0 268.4 
Total current liabilities
2,609.3 2,142.0 
Long-term finance lease liabilities442.3 509.8 
Long-term operating lease liabilities382.3 377.4 
Long-term contingent consideration
127.2 186.5 
Other long-term liabilities
115.7 116.8 
Total liabilities
3,676.8 3,332.5 
Commitments and contingencies— — 
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 256,645,737 and 254,479,046 shares issued and outstanding, respectively
2.6 2.5 
Additional paid-in capital7,225.5 6,880.8 
Accumulated other comprehensive income97.6 15.9 
Retained earnings
5,703.9 3,200.8 
Total shareholders’ equity
13,029.6 10,100.0 
Total liabilities and shareholders’ equity
$16,706.4 $13,432.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(unaudited)
(in millions)
Three Months Ended
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive (Loss) IncomeRetained EarningsTotal Shareholders’ Equity
SharesAmount
Balance at June 30, 2021259.1 $2.6 $7,640.2 $(25.2)$1,578.8 $9,196.4 
Other comprehensive income, net of tax— — — 36.7 — 36.7 
Net income— — — — 851.9 851.9 
Repurchase of common stock(3.3)(0.0)(642.2)— — (642.2)
Common stock withheld for employee tax obligations(0.1)(0.0)(28.6)— — (28.6)
Issuance of common stock under benefit plans0.5 0.0 12.9 — — 12.9 
Stock-based compensation expense
— — 103.7 — — 103.7 
Balance at September 30, 2021256.2 $2.6 $7,086.0 $11.5 $2,430.7 $9,530.8 
Balance at June 30, 2022256.0 $2.6 $7,100.0 $57.5 $4,773.4 $11,933.5 
Other comprehensive income, net of tax— — — 40.1 — 40.1 
Net income— — — — 930.5 930.5 
Common stock withheld for employee tax obligations(0.2)(0.0)(48.0)— — (48.0)
Issuance of common stock under benefit plans0.8 0.0 38.2 — — 38.2 
Stock-based compensation expense
— — 135.3 — — 135.3 
Balance at September 30, 2022256.6 $2.6 $7,225.5 $97.6 $5,703.9 $13,029.6 
Nine Months Ended
Common StockAdditional
Paid-in Capital		Accumulated Other Comprehensive (Loss) IncomeRetained EarningsTotal
Shareholders’ Equity
SharesAmount
Balance at December 31, 2020259.9 $2.6 $7,894.0 $(68.5)$858.7 $8,686.8 
Other comprehensive income, net of tax— — — 80.0 — 80.0 
Net income
— — — — 1,572.0 1,572.0 
Repurchase of common stock(5.3)(0.0)(1,067.2)— — (1,067.2)
Common stock withheld for employee tax obligations(0.6)(0.0)(134.2)— — (134.2)
Issuance of common stock under benefit plans2.2 0.0 66.8 — — 66.8 
Stock-based compensation expense
— — 326.6 — — 326.6 
Balance at September 30, 2021256.2 $2.6 $7,086.0 $11.5 $2,430.7 $9,530.8 
Balance at December 31, 2021254.5 $2.5 $6,880.8 $15.9 $3,200.8 $10,100.0 
Other comprehensive income, net of tax— — — 81.7 — 81.7 
Net income
— — — — 2,503.1 2,503.1 
Common stock withheld for employee tax obligations(0.7)(0.0)(169.9)— — (169.9)
Issuance of common stock under benefit plans2.8 0.1 135.2 — — 135.3 
Stock-based compensation expense
— — 379.4 — — 379.4 
Balance at September 30, 2022256.6 $2.6 $7,225.5 $97.6 $5,703.9 $13,029.6 
The accompanying notes are an integral part of these condensed consolidated financial statements.

5
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in millions)
Nine Months Ended September 30,
20222021
Cash flows from operating activities:
Net income
$2,503.1 $1,572.0 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense379.8 322.8 
Depreciation expense109.9 91.8 
Decrease in fair value of contingent consideration(59.3)(1.1)
Deferred income taxes(424.0)(112.7)
Gains (losses) on equity securities143.1 (5.0)
Other non-cash items, net(32.8)20.5 
Changes in operating assets and liabilities:
Accounts receivable, net(368.8)(231.2)
Inventories(58.1)(65.8)
Prepaid expenses and other assets(41.9)(107.7)
Accounts payable(39.1)(22.0)
Accrued expenses980.3 254.2 
Other liabilities(40.7)(67.3)
Net cash provided by operating activities
3,051.5 1,648.5 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(417.8)(447.8)
Maturities of available-for-sale debt securities435.9 452.1 
Payment to acquire ViaCyte, Inc., net of cash acquired(295.9)— 
Purchases of property and equipment(171.1)(173.2)
Investment in equity securities and notes receivable(47.8)(38.0)
Net cash used in investing activities
(496.7)(206.9)
Cash flows from financing activities:
Issuances of common stock under benefit plans134.7 67.3 
Repurchases of common stock
— (1,057.2)
Payments in connection with common stock withheld for employee tax obligations
(169.9)(134.2)
Payments on finance leases
(75.1)(34.6)
Proceeds from finance leases
— 12.6 
Other financing activities2.4 4.3 
Net cash used in financing activities
(107.9)(1,141.8)
Effect of changes in exchange rates on cash
(70.0)(8.5)
Net increase in cash, cash equivalents and restricted cash2,376.9 291.3 
Cash, cash equivalents and restricted cash—beginning of period
6,800.1 5,988.9 
Cash, cash equivalents and restricted cash—end of period
$9,177.0 $6,280.2 
Supplemental disclosure of cash flow information:
Cash paid for interest
$41.1 $42.7 
Cash paid for income taxes
$840.1 $381.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

A.Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of operations. To conform prior periods to current presentation, we reclassified $26.7 million and $986.8 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and nine months ended September 30, 2021, respectively. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
B.Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
TRIKAFTA/KAFTRIO$2,010.5 $1,555.8 $5,665.3 $4,004.6 
SYMDEKO/SYMKEVI38.2 81.4 145.7 340.0 
ORKAMBI146.2 184.5 399.9 624.2 
KALYDECO139.4 162.4 417.1 532.0 
Total product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Product Revenues by Geographic Location
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
United States$1,455.6 $1,382.9 $4,238.9 $3,893.2 
Outside of the United States
Europe730.5 518.8 2,018.3 1,382.7 
Other
148.2 82.4 370.8 224.9 
Total product revenues outside of the United States878.7 601.2 2,389.1 1,607.6 
Total product revenues, net
$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Contract Liabilities
We had contract liabilities of $119.5 million and $171.7 million as of September 30, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
C.Acquired In-Process Research and Development and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $29.0 million and $92.9 million for the three and nine months ended September 30, 2022, respectively, and $26.7 million and $986.8 million, for the three and nine months ended September 30, 2021, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three and nine months ended September 30, 2022 and 2021, or were new or materially revised during the three and nine months ended September 30, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), formerly known as CTX001, for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we lead global development, manufacturing and commercialization of exa-cel, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including exa-cel) throughout the world subject to CRISPR’s reserved right to conduct certain activities.

9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Acquired in-process research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to exa-cel pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, subject to certain adjustments, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three and nine months ended September 30, 2022 and 2021, we recognized the following amounts in total, not including amounts recorded to “Acquired in-process research and development expenses,” related to these agreements:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Total expenses incurred under the Original CTX001 JDCA and A&R JDCA$98.2 $58.7 $259.8 $147.4 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
$59.0 $35.2 $155.9 $79.6 
Verve Therapeutics, Inc.
In July 2022, we entered into a research collaboration with Verve Therapeutics, Inc. (“Verve”) focused on discovering and developing an in vivo gene-editing program for a liver disease. Under the terms of the agreement, we made a $25.0 million upfront payment to Verve and purchased $35.0 million of Verve’s common stock. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” The investment in Verve’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”
Asset Acquisition
Catalyst Biosciences, Inc. - Complement 3 Degrader Program
In May 2022, pursuant to an asset purchase agreement, we acquired Catalyst Biosciences, Inc.’s portfolio of protease medicines that target the complement system (the “complement portfolio”) and related intellectual property, including CB 2782-PEG, which is a pre-clinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration. We determined that substantially all the fair value acquired was concentrated in the CB-2782 PEG in-process research and development assets, which did not constitute a business, and for which we determined there was no alternative future use. As a result, we recorded our $60.0 million upfront payment to “Acquired in-process research and development expenses” in the nine months ended September 30, 2022.
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”

10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

D.Business Combination
On September 27, 2022, we acquired all outstanding shares of ViaCyte, Inc. (“ViaCyte”), a privately held biotechnology company primarily focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, in exchange for $315.0 million. ViaCyte’s intellectual property and assembled workforce complement our ongoing programs and have the potential to produce therapies for patients with type 1 diabetes. We accounted for the transaction as a business combination, and allocated the purchase price to the following assets acquired and liabilities assumed:
As of September 27, 2022
(in millions)
Cash and cash equivalents$19.1 
Goodwill73.0 
Intangible asset216.6 
Net other assets
6.3 
Total purchase price
$315.0 
The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets acquired and liabilities assumed. The goodwill is attributable to (i) the technological expertise in cell therapy of ViaCyte’s assembled workforce, (ii) the potential synergies from combining ViaCyte’s technology with our clinical development capabilities and (iii) the potential future benefits for other therapeutic programs that the acquired technology could be used for, but did not meet the definition of an in-process research and development asset. None of the goodwill is expected to be deductible for income tax purposes.
The “Intangible asset” is an in-process research and development asset of $216.6 million related to ViaCyte’s technology and intellectual property associated with stem cell differentiation and manufacturing. The fair value of the intangible asset was determined through a discounted cash flow analysis using the relief from royalty method, which estimated the cost savings associated with owning an asset instead of paying a royalty to the previous owner. The relief from royalty method utilized Level 3 fair value inputs including (i) estimated future product sales, which were calculated using, among other assumptions, an estimated probability of obtaining marketing approval for the asset, (ii) estimated after-tax royalty savings expected from ownership of the asset, and (iii) an appropriate discount and tax rate.
As of September 30, 2022, our analysis of the fair value of certain assets acquired, including certain tax analyses, related to the ViaCyte business combination is preliminary and will be finalized during the measurement period of up to one year from the acquisition date. The financial results of ViaCyte did not have a material effect on our condensed consolidated statement of operations in the three and nine months ended September 30, 2022.


11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
E.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions, except per share amounts)
Net income$930.5 $851.9 $2,503.1 $1,572.0 
Basic weighted-average common shares outstanding256.5 257.9 255.8 258.7 
Effect of potentially dilutive securities:
Stock options1.4 1.0 1.4 1.1 
Restricted stock units (including PSUs)
1.6 0.8 1.4 1.1 
Employee stock purchase program
0.0 0.0 0.1 0.0 
Diluted weighted-average common shares outstanding259.5 259.7 258.7 260.9 
Basic net income per common share$3.63 $3.30 $9.78 $6.08 
Diluted net income per common share$3.59 $3.28 $9.68 $6.03 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Stock options— 1.1 0.0 0.7 
Unvested restricted stock units (including PSUs)0.0 0.2 0.2 0.4 

F.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note G, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.

12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively):
As of September 30, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$3,610.9 $3,610.9 $— $— $3,478.1 $3,478.1 $— $— 
Time deposits2,000.0 — 2,000.0 — — — — — 
Commercial paper18.2 — 18.2 — — — — — 
Marketable securities:
Corporate equity securities122.8 78.2 44.6 — 230.9 230.9 — — 
U.S. Treasury securities130.0 130.0 — — 86.4 86.4 — — 
Government-sponsored enterprise securities
10.5 10.5 — — 69.0 69.0 — — 
Corporate debt securities
66.8 — 66.8 — 90.9 — 90.9 — 
Commercial paper
269.1 — 269.1 — 252.7 — 252.7 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts191.6 — 191.6 — 44.5 — 44.5 — 
Other assets:
Foreign currency forward contracts9.1 — 9.1 — 2.0 — 2.0 — 
Total financial assets
$6,429.0 $3,829.6 $2,599.4 $— $4,254.5 $3,864.4 $390.1 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(0.0)$— $(0.0)$— $(5.6)$— $(5.6)$— 
Long-term contingent consideration
(127.2)— — (127.2)(186.5)— — (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(0.0)— (0.0)— (2.7)— (2.7)— 
Total financial liabilities
$(127.2)$— $(0.0)$(127.2)$(194.8)$— $(8.3)$(186.5)
Please refer to Note G, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note G, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy and other severe neuromuscular diseases, including myotonic dystrophy type 1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.2% and 5.7% as of September 30, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and

13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Nine Months Ended September 30, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(59.3)
Balance at September 30, 2022$127.2 
The decrease in fair value of contingent consideration during the nine months ended September 30, 2022 was primarily due to a revision to the scope of certain acquired gene-editing programs in the second quarter of 2022.
Fair Value of Intangible Assets
As of September 30, 2022 and December 31, 2021, we had $603.6 million and $400.0 million, respectively, of in-process research and development intangible assets classified as “Intangible assets” on our condensed consolidated balance sheets. In the third quarter of 2022, we recorded a $216.6 million in-process research and development intangible asset resulting from our acquisition of ViaCyte, which is described in Note D, “Business Combination.” In the nine months ended September 30, 2022, we recorded a $13.0 million impairment of an in-process research and development intangible asset to “Research and development expenses,” due to a decision to revise the scope of certain acquired gene-editing programs.

G.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively), is shown below:
As of September 30, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$3,610.9 $— $— $3,610.9 $3,478.1 $— $— $3,478.1 
Time deposits2,000.0 — — 2,000.0 — — — — 
Commercial paper18.2 — — 18.2 — — — — 
Total cash equivalents
$5,629.1 $— $— $5,629.1 $3,478.1 $— $— $3,478.1 
Marketable securities:
U.S. Treasury securities$131.7 $— $(1.7)$130.0 $86.6 $— $(0.2)$86.4 
Government-sponsored enterprise securities
10.6 — (0.1)10.5 69.0 — — 69.0 
Corporate debt securities
67.8 — (1.0)66.8 91.1 — (0.2)90.9 
Commercial paper
270.4 — (1.3)269.1 252.8 — (0.1)252.7 
Total marketable debt securities
480.5 — (4.1)476.4 499.5 — (0.5)499.0 
Corporate equity securities
104.4 29.2 (10.8)122.8 69.4 167.1 (5.6)230.9 
Total marketable securities
$584.9 $29.2 $(14.9)$599.2 $568.9 $167.1 $(6.1)$729.9 

14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of September 30, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$3,629.1 $3,478.1 
Marketable securities
476.4 499.0 
Total
$4,105.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of September 30, 2022As of December 31, 2021
(in millions)
Matures within one year$4,091.4 $3,912.3 
Matures after one year through five years
14.1 64.8 
Total
$4,105.5 $3,977.1 
We have a limited number of available-for-sale debt securities in insignificant loss positions as of September 30, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three and nine months ended September 30, 2022 and 2021.
We record changes in the fair value of our investments in corporate equity securities to “Other income (expense), net” in our condensed consolidated statements of operations. During the three and nine months ended September 30, 2022 and 2021, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Net unrealized gains (losses)
$16.7 $46.7 $(143.1)$5.0 
        
As of September 30, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.


15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
H.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(42.8)(3.6)230.2 183.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (102.1)(102.1)
Net current period other comprehensive (loss) income(42.8)(3.6)128.1 81.7 
Balance at September 30, 2022$(56.4)$(4.1)$158.1 $97.6 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications3.3 (0.3)46.2 49.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — 30.8 30.8 
Net current period other comprehensive income (loss)3.3 (0.3)77.0 80.0 
Balance at September 30, 2021$(12.3)$0.0 $23.8 $11.5 

I.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2022, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of September 30, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.

16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of September 30, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,081.9 $1,364.5 
Canadian dollar
192.3 89.9 
British pound sterling
183.5 287.7 
Australian dollar
150.8 96.3 
Swiss Franc59.2 54.1 
Total foreign currency forward contracts
$1,667.7 $1,892.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income (expense), net” in our condensed consolidated statements of operations each period. As of September 30, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $641.6 million.
During the three and nine months ended September 30, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$65.2 $(5.2)$130.3 $(39.3)
Not designated as hedging instruments
Other income (expense), net$(22.1)$(0.4)$(38.9)$(9.4)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Other income (expense), net$17.2 $42.4 $(133.7)$(2.2)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of September 30, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$191.6 Other current liabilities$(0.0)
Other assets9.1 Other long-term liabilities(0.0)
Total assets
$200.7 
Total liabilities
$(0.0)

17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of September 30, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of September 30, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$200.7 $— $200.7 $(0.0)$200.7 
Total liabilities(0.0)— (0.0)0.0 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 

J.Inventories
Inventories consisted of the following:
As of September 30, 2022As of December 31, 2021
(in millions)
Raw materials$32.2 $42.4 
Work-in-process229.3 224.0 
Finished goods
126.7 86.7 
Total
$388.2 $353.1 


18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
K.Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three and nine months ended September 30, 2022 and 2021, we recognized the following stock-based compensation expense:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$130.3 $89.5 $351.5 $279.1 
Stock options3.1 7.9 14.9 29.6 
ESPP share issuances1.9 6.3 13.0 17.9 
Stock-based compensation expense related to inventories
0.3 (0.7)0.4 (3.8)
Total stock-based compensation expense included in “Total costs and expenses”
$135.6 $103.0 $379.8 $322.8 
Stock-based compensation expense by line item:
Cost of sales$2.4 $1.6 $7.0 $4.6 
Research and development expenses80.0 61.0 229.9 196.4 
Selling, general and administrative expenses53.2 40.4 142.9 121.8 
Total stock-based compensation expense included in costs and expenses
135.6 103.0 379.8 322.8 
Income tax effect(38.8)(21.6)(101.3)(73.7)
Total stock-based compensation expense, net of tax
$96.8 $81.4 $278.5 $249.1 
Share repurchase programs
In November 2020, our Board of Directors approved a share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and the first quarter of 2021. During the three months ended March 31, 2021, we repurchased 2.0 million shares of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million.
In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the nine months ended September 30, 2022, we did not repurchase any shares of our common stock under the 2021 Share Repurchase Program. As of September 30, 2022, a total of $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.


19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
L.Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three and nine months ended September 30, 2022 and 2021, we recorded the following provisions for (benefits from) income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions, except percentages)
Income before provision for income taxes$1,176.4 $1,082.8 $3,155.6 $1,859.5 
Provision for income taxes245.9 230.9 652.5 287.5 
Effective tax rate21 %21 %21 %15 %
Our effective tax rate for the three and nine months ended September 30, 2022, and the three months ended September 30, 2021, was similar to the U.S. statutory rate.
Our effective tax rate for the nine months ended September 30, 2021 was different than the U.S. statutory rate primarily due to a $99.7 million discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2022 and December 31, 2021, we had $144.9 million and $129.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
Starting in 2022, our cash paid for income taxes is substantially increasing due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Jobs Act of 2017, amortize them over a five year period if they are performed in the U.S. and fifteen years if they are performed in foreign jurisdictions.
In August 2022, the Inflation Reduction Act of 2022 (“IRA”) was enacted into law. The IRA includes a 15% corporate alternative minimum tax and a 1% excise tax on share repurchases. We do not expect the IRA to have a significant impact on our consolidated financial statements.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018 in jurisdictions that have a material impact on our consolidated financial statements.

M.Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a SOFR rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).

20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of September 30, 2022, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Prior Credit Facilities
In July 2022, in conjunction with entering our new credit agreement, we terminated the $500.0 million credit agreement we entered into in 2019. In September 2022, a $2.0 billion credit agreement we entered into in 2020 expired in accordance with its terms.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note F, “Fair Value Measurements,” there were no material contingent liabilities accrued as of September 30, 2022 or December 31, 2021.


21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
N.Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Nine Months Ended September 30,
20222021
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$6,795.0 $9,171.5 $5,988.2 $6,275.7 
Prepaid expenses and other current assets
5.1 5.5 0.7 4.5 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$6,800.1 $9,177.0 $5,988.9 $6,280.2 


22
Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have four approved medicines to treat cystic fibrosis, or CF, a life-threatening genetic disease, and are focused on increasing the number of people with CF eligible and able to receive our medicines through label expansions, approval of new medicines, and expanded reimbursement. We are broadening our pipeline into additional disease areas through internal research efforts and accessing external innovation through business development transactions.
Our triple combination regimen, TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), was approved in 2019 in the United States, or U.S., and in 2020 in the European Union, or E.U. Collectively, our four medicines are being used by the majority of the approximately 83,000 people with CF in North America, Europe, and Australia. We are evaluating our medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for approximately 90% of people with CF. We also are pursuing genetic therapies for the remaining people with CF who may not be helped by our current CF medicines.
Beyond CF, we continue to research and develop product candidates for the treatment of serious diseases, including sickle cell disease, beta thalassemia, pain, APOL1-mediated kidney disease, type 1 diabetes, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and myotonic dystrophy type 1.
Financial Highlights
Revenues
In the third quarter of 2022, our net product revenues continued to increase as compared to the third quarter of 2021 primarily due to the strong uptake of TRIKAFTA/KAFTRIO in multiple countries internationally and continued steady performance of TRIKAFTA in the U.S.
Expenses
Our total research and development, or R&D, acquired in-process research and development, or AIPR&D, and selling, general and administrative, or SG&A, expenses increased to $920.8 million in the third quarter of 2022 as compared to $691.9 million in the third quarter of 2021. The increase was primarily due to the progression of several product candidates into mid- to late-stage clinical development. Cost of sales was 12% of our net product revenues in each of the third quarter of 2022 and 2021, respectively.
Cash
Our cash, cash equivalent and marketable securities increased to $9.8 billion as of September 30, 2022 as compared to $7.5 billion as of December 31, 2021 primarily due to our net product revenues and operating cash flows partially offset by income tax payments and our acquisition of ViaCyte, Inc., or ViaCyte.
vrtx-20220930_g1.gif

23
Business Updates
Marketed Products
We expect to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines. Recent and anticipated progress in activities supporting these efforts is included below.
•We have received approval from the U.S. Food and Drug Administration, or the FDA, for ORKAMBI in children with CF 12 to less than 24 months of age who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.
•We have received reimbursement of KAFTRIO in Italy for children with CF 6 to 11 years of age with at least one F508del mutation in the CFTR gene.
•We expect to present results from the Phase 3 clinical trial for TRIKAFTA/KAFTRIO in children with CF 2 to 5 years of age at the North American Cystic Fibrosis Conference in November 2022. We anticipate global regulatory submissions for TRIKAFTA/KAFTRIO in children with CF 2 to 5 years of age before the end of 2022.
•We anticipate global regulatory submissions for KALYDECO in children with CF from 1 month to less than 4 months of age before the end of 2022.
•TRIKAFTA/KAFTRIO is now approved and reimbursed or accessible in more than 30 countries.
Pipeline
We continue to advance a pipeline of potentially transformative small molecule and cell and genetic therapies aimed at treating serious diseases. Recent and anticipated progress in activities supporting these efforts is included below.
Cystic Fibrosis
•We are conducting two Phase 3 global, randomized, double-blind, active-controlled clinical trials evaluating our new once-daily investigational triple combination of vanzacaftor/tezacaftor/deutivacaftor, formerly known as VX-121/tezacaftor/VX-561, in people with CF 12 years of age and older. Enrollment in both clinical trials is expected to be completed by the end of 2022. We also have initiated a clinical trial of vanzacaftor/tezacaftor/deutivacaftor in children with CF 6 to 11 years of age.
•In collaboration with Moderna, we are developing a CFTR mRNA therapeutic for the treatment of people with CF who do not produce any CFTR protein. We have completed IND-enabling studies and expect to submit an Investigational New Drug Application, or IND, for this program in the fourth quarter of 2022.
Beta Thalassemia and Sickle Cell Disease
•We are evaluating the use of a non-viral ex vivo CRISPR gene-editing therapy, exagamglogene autotemcel, or exa-cel, formerly known as CTX001, for the treatment of sickle cell disease, or SCD, and transfusion-dependent beta thalassemia, or TDT. We have concluded our discussions with the FDA, and the FDA granted exa-cel a rolling review. We plan to submit a biologics licensing application, or BLA, beginning in November 2022. We expect to complete the submission by the end of the first quarter of 2023. In the U.S., exa-cel has been granted Fast Track, Regenerative Medicine Advanced Therapy, Rare Pediatric Disease, and Orphan Drug designations.
•We anticipate submissions to the European Medicines Agency, or EMA, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency, or MHRA, for regulatory approval of exa-cel for TDT and SCD in Europe and the U.K. in the fourth quarter of 2022. Exa-cel has been granted EMA Priority Medicines, or PRIME, designation in Europe and Orphan Drug designation in Europe and the U.K.
•Two additional Phase 3 clinical trials evaluating exa-cel in pediatric patients with TDT and SCD are ongoing.

24
Pain
•We have discovered multiple selective small molecule inhibitors of NaV1.8 with the objective of creating a new class of pain medicines that have the potential to provide effective pain relief. In March, we announced positive Phase 2 data for VX-548, a NaV1.8 inhibitor, for the non-opioid treatment of acute pain. We have reached agreement with the FDA on the Phase 3 pivotal program design for VX-548 for moderate to severe acute pain. We have initiated this Phase 3 program and we expect to enroll two randomized, controlled trials with 2,000 patients with moderate to severe acute pain following bunionectomy and abdominoplasty surgery. We plan to evaluate the safety and effectiveness of VX-548 in multiple other types of moderate to severe acute pain in an additional clinical trial.
•The FDA granted VX-548 Fast Track and Breakthrough Therapy designations for the treatment of moderate to severe acute pain.
•We expect to initiate a Phase 2 clinical trial evaluating VX-548 in neuropathic pain by the end of 2022.
APOL1-Mediated Kidney Disease
•Inaxaplin, formerly known as VX-147, is our small molecule for the treatment of APOL1-mediated kidney disease, or AMKD, including APOL1-mediated focal segmental glomerulosclerosis, or FSGS. Based on positive Phase 2 data in FSGS, we initiated pivotal development of inaxaplin in a single Phase 2/3 clinical trial in patients with AMKD with two APOL1 mutations and proteinuric kidney disease. We continue to enroll patients in this Phase 2/3 clinical trial.
•The FDA granted inaxaplin Breakthrough Therapy designation for APOL1-mediated FSGS and the EMA granted inaxaplin Orphan Drug and PRIME designations for AMKD.
Type 1 Diabetes
•VX-880 is a stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy used in combination with immunosuppression to protect the implanted cells. VX-880 is being evaluated in a Phase 1/2 clinical trial as a potential treatment for type 1 diabetes, or T1D, and proof-of-concept has been achieved in the VX-880 program. Enrollment is ongoing in this Phase 1/2 clinical trial.
•We continue to advance additional programs in T1D, in which these same stem cell-derived, fully differentiated, insulin-producing islet cells are encapsulated and implanted in an immunoprotective device or modified to produce hypoimmune stem cells islets with the goal of eliminating the need for immunosuppression. We are conducting IND-enabling studies for the cells and device program, and we expect to submit an IND for this program in the fourth quarter of 2022.
Alpha-1 Antitrypsin Deficiency
•We are working to address the underlying genetic cause of alpha-1 antitrypsin, or AAT, deficiency by developing novel small molecule correctors of Z-AAT protein folding, with the goal of enabling the secretion of functional AAT into the blood and addressing both the lung and the liver aspects of AAT deficiency. We have initiated a clinical trial for VX-634, which is the first in a series of next-wave investigational molecules with significantly improved potency and drug-like properties as compared to our previous AAT correctors.
•We plan to initiate a Phase 2 clinical trial of VX-864, a first-generation AAT corrector, to assess the impact of longer-term treatment on the liver, as well as the levels of functional AAT in the plasma.
Duchenne Muscular Dystrophy
•We are investigating a novel approach to treating Duchenne muscular dystrophy, or DMD, which delivers CRISPR/Cas9 gene-editing technology to muscle cells, with the goal of restoring near-full length dystrophin protein expression by targeting specific mutations in the dystrophin gene that cause the disease. We are conducting IND-enabling studies for our first in vivo gene-editing therapy for DMD and we expect to submit an IND for this program in 2023.

25
Investment in External Innovation
•In the third quarter of 2022, we acquired ViaCyte, a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a potential functional cure for T1D.
Our Business Environment
Our net product revenues come from the sale of our medicines for the treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to receive our medicines, including through label expansions, expanded reimbursement, and the development of new medicines. We are actively pursuing a pipeline of product candidates for the treatment of serious diseases outside of CF. Our strategy is to combine transformative advances in the understanding of human disease biology and the science of therapeutics in order to discover and develop new medicines. This approach includes advancing multiple compounds from each program, spanning multiple modalities, into early clinical trials and evaluating patient data to inform discovery and development of additional compounds, with the goal of bringing first-in-class and best-in-class therapies to patients, and to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Most potential drug or biological products never progress into development, and most products that do advance into development never receive marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
Our business also requires ensuring appropriate manufacturing and reimbursement of our products. As we advance our product candidates through clinical development toward commercialization and market and sell our approved products, we build and maintain our supply chain and quality assurance resources. We rely on a global network of third parties and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for each new approved product, we adapt our supply chain for existing products to include additional formulations or to increase scale of production for existing products as needed. The processes for cell and genetic therapies can be more complex than those required for small molecule drugs and require different systems, equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets.
In the U.S., we have worked successfully with third-party payors in order to promptly obtain appropriate levels of reimbursement for our CF medicines. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide and provide patients with appropriate levels of access to our medicines now and in the future. In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region basis, as required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to continue to focus significant resources to obtain expanded reimbursement for our CF medicines and, ultimately, pipeline therapies in U.S. and ex-U.S. markets.

26
COVID-19
We continue to monitor the impacts of the COVID-19 global pandemic on our business, including in our clinical trials, manufacturing facilities and capabilities, and ability to access necessary resources. COVID-19 has not materially affected our supply chain or the demand for our medicines, and we believe that we will be able to continue to supply all of our approved medicines to patients globally. We adjusted our business operations in response to COVID-19 and have continued to monitor local COVID-19 trends and government guidance for each of our site locations. We are utilizing a site-specific approach to assess and permit employee access to our sites. Currently, our sites are open to certain employees where appropriate and permitted by local laws and guidelines.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire products, product candidates and other technologies and businesses that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts.
In the second quarter of 2022, we acquired Catalyst Biosciences, Inc.’s, or Catalyst’s, portfolio of protease medicines that target the complement system and related intellectual property for $60.0 million. In the third quarter of 2022, we acquired ViaCyte, a privately held biotechnology company with intellectual property, tools, technologies and assets with potential to accelerate development of our T1D programs, for $315.0 million.
We expect to continue to identify and evaluate potential acquisitions and may include larger transactions or later-stage assets.
Collaboration and In-Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of products, product candidates and other technologies that have the potential to complement our ongoing research and development efforts. Over the last several years, we entered into collaboration agreements with a number of companies, including Arbor Biotechnologies, Inc., CRISPR Therapeutics AG, Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., and Verve Therapeutics, Inc., or Verve. Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option payments. Most of these collaboration payments are expensed as acquired in-process research and development expenses; however, depending on many factors, including the structure of the collaboration, the significance of the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
Acquired In-Process Research and Development
In the nine months ended September 30, 2022 and 2021, our AIPR&D included $92.9 million and $986.8 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the collaborations, licenses of third-party technologies, and asset acquisitions described above.
Out-License Agreements
We also have out-licensed internally developed programs to collaborators who are leading the development of these programs. Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development, and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs. None of our out-license agreements had

27
a significant impact on our condensed consolidated statement of operations during the nine months ended September 30, 2022 and 2021.
Strategic Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of September 30, 2022, we held strategic equity investments in certain public and private companies, and we expect to make additional strategic equity investments in the future. While we invest the majority of our cash, cash equivalents and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or type of instrument, our strategic investments are maintained and managed separately from our other cash, cash equivalents and marketable securities. As discussed below in “Other Income (Expense), Net” in our Results of Operations, any changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities) are recorded to other income (expense), net in our condensed consolidated statement of operations.


28
RESULTS OF OPERATIONS
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages and per share amounts)
Revenues$2,334.3 $1,984.1 18%$6,628.0 $5,501.8 20%
Operating costs and expenses1,207.6 929.6 30%3,354.1 3,597.4 (7)%
Income from operations
1,126.7 1,054.5 7%3,273.9 1,904.4 72%
Other non-operating expense, net49.7 28.3 76%(118.3)(44.9)163%
Provision for income taxes
245.9 230.9 6%652.5 287.5 127%
Net income
$930.5 $851.9 9%$2,503.1 $1,572.0 59%
Net income per diluted common share$3.59 $3.28 $9.68 $6.03 
Diluted shares used in per share calculations
259.5 259.7 258.7 260.9 
Revenues
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
TRIKAFTA/KAFTRIO$2,010.5 $1,555.8 29%$5,665.3 $4,004.6 41%
SYMDEKO/SYMKEVI38.2 81.4 (53)%145.7 340.0 (57)%
ORKAMBI146.2 184.5 (21)%399.9 624.2 (36)%
KALYDECO139.4 162.4 (14)%417.1 532.0 (22)%
Product revenues, net2,334.3 1,984.1 18%6,628.0 5,500.8 20%
Other revenues— — **— 1.0 **
Total revenues$2,334.3 $1,984.1 18%$6,628.0 $5,501.8 20%
** Not meaningful
Product Revenues, Net
In the third quarter of 2022, our net product revenues increased by $350.2 million, or 18% as compared to the third quarter of 2021, primarily due to the strong uptake of TRIKAFTA/KAFTRIO in multiple countries internationally and continued steady performance of TRIKAFTA in the U.S. In the nine months ended September 30, 2022, our net product revenues increased by $1.1 billion, or 20% as compared to the nine months ended September 30, 2021, respectively, primarily due to the strong uptake of TRIKAFTA/KAFTRIO in multiple countries internationally and in the U.S., including the June 2021 launch of TRIKAFTA for children with CF 6 through 11 years or age. Decreases in revenues for our products other than TRIKAFTA/KAFTRIO were primarily the result of patients switching from these medicines to TRIKAFTA/KAFTRIO.
Our net product revenues from the U.S. and from ex-U.S. markets were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
United States$1,455.6 $1,382.9 5%$4,238.9 $3,893.2 9%
ex-U.S.878.7 601.2 46%2,389.1 1,607.6 49%
Product revenues, net$2,334.3 $1,984.1 18%$6,628.0 $5,500.8 20%

29
Other Revenues
We earned a collaborative milestone of $1.0 million in the nine months ended September 30, 2021 and did not have any “Other revenues” in the nine months ended September 30, 2022. Our “Other revenues” have historically fluctuated significantly from one period to another based on our collaborative out-license activities and may continue to fluctuate in the future.
Operating Costs and Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
Cost of sales$289.4 $236.5 22%$797.0 $656.8 21%
Research and development expenses645.0 467.0 38%1,846.2 1,370.0 35%
Acquired in-process research and development expenses29.0 26.7 9%92.9 986.8 (91)%
Selling, general and administrative expenses246.8 198.2 25%677.3 584.9 16%
Change in fair value of contingent consideration(2.6)1.2 **(59.3)(1.1)**
Total costs and expenses$1,207.6 $929.6 30%$3,354.1 $3,597.4 (7)%
** Not meaningful
In the second quarter of 2022, we began classifying upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses,” or “AIPR&D,” in our condensed consolidated statements of operations. To conform prior periods to our current presentation, we have reclassified $26.7 million and $986.8 million from “Research and development expenses” to “AIPR&D” for the third quarter and nine months ended September 30, 2021, respectively.
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our products as well as the cost of producing inventories. Pursuant to our agreement with the Cystic Fibrosis Foundation our tiered third-party royalties on sales of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with royalties on sales of TRIKAFTA/KAFTRIO slightly lower than for our other products. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues was 12% in each of the third quarter and nine months ended September 30, 2022 and 2021.
Research and Development Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
Research expenses$160.2 $121.9 31%$464.9 $372.2 25%
Development expenses
484.8 345.1 40%1,381.3 997.8 38%
Total research and development expenses
$645.0 $467.0 38%$1,846.2 $1,370.0 35%
Our research and development expenses include internal and external costs incurred for research and development of our products and product candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual products or product candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. We assign external costs of services provided to us by clinical research organizations and other

30
outsourced research by individual program. Our internal costs are significantly greater than our external costs. All research and development costs for our products and product candidates are expensed as incurred.
Since January 2020, we have incurred approximately $6.8 billion in total research and development and AIPR&D expenses associated with product discovery and development. The successful development of our product candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the product candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our product candidates to market are not available.
Any estimates regarding development and regulatory timelines for our product candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
Research Expenses:
Salary and benefits$40.7 $34.6 18%$119.0 $102.5 16%
Stock-based compensation expense23.3 17.4 34%65.7 56.4 16%
Outsourced services and other direct expenses49.2 35.8 37%132.7 114.9 15%
Intangible asset impairment charge— — **13.0 — **
Infrastructure costs
47.0 34.1 38%134.5 98.4 37%
Total research expenses
$160.2 $121.9 31%$464.9 $372.2 25%
** Not meaningful
Our research expenses have been increasing over the last several years as we have invested in our pipeline and expanded our cell and genetic therapy capabilities, resulting in increased headcount and infrastructure. We expect to continue to invest in our research programs with a focus on creating transformative medicines for serious diseases.
Development Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
Development Expenses:
Salary and benefits$133.5 $88.6 51%$344.4 $252.2 37%
Stock-based compensation expense56.7 43.6 30%164.2 140.0 17%
Outsourced services and other direct expenses215.9 149.6 44%639.2 426.4 50%
Infrastructure costs
78.7 63.3 24%233.5 179.2 30%
Total development expenses
$484.8 $345.1 40%$1,381.3 $997.8 38%

31
Our development expenses increased by $139.7 million and $383.5 million, or 40% and 38%, in the third quarter and nine months ended September 30, 2022 as compared to the third quarter and nine months ended September 30, 2021, respectively, primarily due to increased costs to support clinical trials associated with our advancing pipeline programs, including our CF triple combination of vanzacaftor/tezacaftor/deutivacaftor, exa-cel, pain and T1D. We are investing in our internal headcount, leveraging outsourced services, and investing in infrastructure to support these programs. In the nine months ended September 30, 2022 and 2021, costs related to our CF programs represented the largest portion of our development costs.
Acquired In-process Research and Development Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
Acquired in-process research and development expenses$29.0 $26.7 9%$92.9 $986.8 (91)%
AIPR&D in the third quarter of 2022 was primarily related to a $25.0 million upfront payment pursuant to our license agreement with Verve. AIPR&D in the nine months ended September 30, 2022 was primarily related to our payment to Verve and a $60.0 million payment to Catalyst to acquire their complement portfolio and related intellectual property. AIPR&D in the nine months ended September 30, 2021 included the $900.0 million upfront payment to CRISPR. Our AIPR&D has historically fluctuated, and is expected to continue to fluctuate, from one period to another due to upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Selling, General and Administrative Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in millions, except percentages)
Selling, general and administrative expenses$246.8 $198.2 25%$677.3 $584.9 16%
Selling, general and administrative expenses increased by 25% and 16% in the third quarter and nine months ended September 30, 2022 as compared to the third quarter and nine months ended September 30, 2021, respectively, primarily due to the continued investment to support the commercialization of our medicines and increased support for our pipeline product candidates.
Contingent Consideration
The fair value of contingent consideration potentially payable to former Exonics equity holders decreased by $2.6 million and $59.3 million in the third quarter and nine months ended September 30, 2022, respectively. The fair value of contingent consideration decreased in the nine months ended September 30, 2022 primarily as a result of a revision to the scope of certain gene-editing programs in the second quarter of 2022. The fair value of contingent consideration increased by $1.2 million and decreased by $1.1 million in the third quarter and nine months ended September 30, 2021, respectively.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income increased to $46.2 million and $58.6 million in the third quarter and nine months ended September 30, 2022, respectively, as compared to $1.1 million and $3.7 million in the third quarter and nine months ended September 30, 2021, respectively. The increase in interest income was primarily due to increased market interest rates and increased cash equivalents and available-for-sale debt securities. Our future interest income is dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and available-for-sale debt securities.

32
Interest Expense
Interest expense was $13.7 million and $15.2 million in the third quarter of 2022 and 2021, respectively, and $43.2 million and $46.4 million in the nine months ended September 30, 2022 and 2021, respectively. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston.
Other Income (Expense), Net
Other income (expense), net was income of $17.2 million and $42.4 million in the third quarter of 2022 and 2021, respectively, and expense of $133.7 million and $2.2 million in the nine months ended September 30, 2022 and 2021, respectively. The vast majority of these amounts relate to net unrealized gains or losses resulting from changes in the fair value of our strategic investments. As of September 30, 2022, the fair value of our investments in publicly traded companies was $122.8 million. To the extent that we continue to hold strategic investments in publicly traded companies, we will record other income (expense) related to these strategic investments on a quarterly basis. We expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic investments.
Income Taxes
We recorded provisions for income taxes of $245.9 million and $652.5 million in the third quarter and nine months ended September 30, 2022, respectively, and $230.9 million and $287.5 million in the third quarter and nine months ended September 30, 2021. Our effective tax rate of 21% for the nine months ended September 30, 2022 was similar to the U.S. statutory rate. Our effective tax rate of 15% for the nine months ended September 30, 2021 was lower than the U.S. statutory rate primarily due to a $99.7 million discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023.
Net Income
Our net income increased to $930.5 million in the third quarter of 2022 as compared to $851.9 million in the third quarter of 2021, primarily due to increased product revenues and interest income partially offset by increased operating costs and expenses.
Our net income increased to $2.5 billion in the nine months ended September 30, 2022 as compared to $1.6 billion in the nine months ended September 30, 2021, primarily due to the $900.0 million upfront payment we made to CRISPR in the second quarter of 2021 and increased product revenues partially offset by increased operating costs and expenses. We also incurred significant unrealized losses on our strategic investments in third quarter and nine months ended September 30, 2022.
In each of the third quarter of 2022 as compared to the third quarter of 2021 and the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021, our increased operating costs and expenses consisted of increased cost of sales, development expenses to progress several product candidates into mid- to late-stage clinical development, selling, general and administrative expenses to support the commercialization of our medicines and increased support for our pipeline product candidates and income taxes.


33
LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of September 30, 2022 and December 31, 2021:
As of September 30, 2022As of December 31, 2021Change
(in millions, except percentages)
Cash, cash equivalents and marketable securities$9,770.7 $7,524.9 30%
Working Capital:
Total current assets12,271.0 9,560.6 28%
Total current liabilities(2,609.3)(2,142.0)22%
Total working capital$9,661.7 $7,418.6 30%
Working Capital
As of September 30, 2022, total working capital was $9.7 billion, which represented an increase of $2.2 billion from $7.4 billion as of December 31, 2021. The increase in total working capital in the nine months ended September 30, 2022 was primarily related to $3.1 billion of cash provided by operations.
Cash Flows
Nine Months Ended September 30,
20222021
(in millions)
Net cash provided by (used in):
Operating activities$3,051.5 $1,648.5 
Investing activities$(496.7)$(206.9)
Financing activities$(107.9)$(1,141.8)
Operating Activities
Cash provided by operating activities were $3.1 billion in the nine months ended September 30, 2022 as compared to $1.6 billion in the nine months ended September 30, 2021, primarily due to the $900.0 million upfront payment to CRISPR in the nine months ended September 30, 2021 and an increase to accrued expenses from increased product revenues, offset by higher income tax payments.
Investing Activities
Cash used in investing activities were $496.7 million and $206.9 million in the nine months ended September 30, 2022 and 2021, respectively. In the third quarter of 2022, our investing activities included a net payment of $295.9 million to acquire ViaCyte. Otherwise, our investing activities were primarily related to purchases of property and equipment in each of the nine months ended September 30, 2022 and 2021.
Financing Activities
Cash used in financing activities were $107.9 million and $1.1 billion in the nine months ended September 30, 2022 and 2021, respectively. In the nine months ended September 30, 2022, the largest portion of our financing activities were related to our employee stock benefit plans. In the nine months ended September 30, 2021, the largest portion of our financing activities were share repurchases pursuant to our share repurchase programs totaling $1.1 billion.
Sources and Uses of Liquidity
As of September 30, 2022, we had cash, cash equivalents and marketable securities of $9.8 billion, which represented an increase of $2.2 billion from $7.5 billion as of December 31, 2021. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.

34
We expect that cash flows from our products together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by our products, and the potential introduction of one or more of our other product candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Credit Facilities & Financing Strategy
We may borrow up to $500.0 million pursuant to a revolving credit facility that we entered into in July 2022 and could repay and reborrow amounts under this revolving credit agreement without penalty. Subject to certain conditions, we could request that the borrowing capacity be increased by an additional $500.0 million, for a total of $1.0 billion. Negative covenants in our credit agreement could prohibit or limit our ability to access this source of liquidity. As of September 30, 2022, the facility was undrawn, and we were in compliance with these covenants.
In July 2022, in conjunction with entering our new credit agreement, we terminated the $500.0 million credit agreement we entered into in 2019. In September 2022, a $2.0 billion credit agreement we entered into in 2020 expired in accordance with its terms.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
Future Capital Requirements
We have significant future capital requirements, including:
•Expected operating expenses to conduct research and development activities and to operate our organization.
•Facility and finance lease obligations.
•Royalties we pay to the Cystic Fibrosis Foundation on sales of our CF products.
•Cash paid for income taxes.
In addition, we have significant potential future capital requirements including:
•We have entered into certain business development-related agreements with third parties that include the funding of certain research, development, and commercialization efforts. Certain of our transactions, including collaborations, licensing arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets. Our obligation to fund these research and development and commercialization efforts and to pay these potential milestone and royalties is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs associated with our collaborations, licensing arrangements and acquisitions. We may enter into additional business development transactions, including acquisitions, collaborations, licensing arrangements and equity investments, that require additional capital.
•To the extent we borrow amounts under our existing credit agreement, we would be required to repay any outstanding principal amounts in 2027.
•As of September 30, 2022, we had $0.5 billion available under our 2021 Share Repurchase Program.
There have not been any material changes to our future capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC, on February 9, 2022.


35
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the nine months ended September 30, 2022, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022.

RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies.”

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022.

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that, based on such evaluation, as of September 30, 2022 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Information

Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.


36
Item 1A. Risk Factors
Information regarding risk factors appears in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I, Item 2, contain a number of forward-looking statements. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to:
•our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses and other gains and losses, including those related to net product revenues;
•our expectations regarding clinical trials, development timelines, regulatory authority filings, submissions, and potential approvals and label expansions for our product and product candidates, and other pipeline programs, including timing and structure of clinical trials, anticipated enrollment and dosing of patients, timing of availability of data from our ongoing and planned clinical trials, and timing of anticipated regulatory filings;
•our ability to obtain reimbursement for our medicines in the U.S. and ex-U.S. markets and our ability to launch, commercialize and market our products or any of our other product candidates for which we obtain regulatory approval;
•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our product candidates and other pipeline programs for further investigation, clinical trials or potential use as a treatment;
•our beliefs regarding the number of people with CF and those potentially eligible for our medicines, and our ability to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines;
•our expectations regarding the potential benefits and commercial potential of our product candidates, including the potential approach to treating or curing specific diseases;
•our plan to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;
•the potential future benefits of our acquisitions and collaborations, including our exa-cel collaboration with CRISPR;
•the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations;
•potential business development activities, including the identification of potential collaborative partners or acquisition targets;
•our expectations that our acquisition of ViaCyte may accelerate the development of our T1D program;
•our expectations regarding the effect of COVID-19 on, among other things, our financial performance, liquidity, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs;
•potential fluctuations in foreign currency exchange rates;
•our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets;

37
•our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs; and
•our liquidity and our expectations regarding the possibility of raising additional capital.
Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements. These risks, uncertainties, and other factors include, but are not limited to, those described in our “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022, and those described from time to time in our future reports filed with the Securities and Exchange Commission.
Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. We did not repurchase any shares of our common stock under the 2021 Share Repurchase Program in the three months ended September 30, 2022. As of September 30, 2022, $499.7 million remained available to fund repurchases under this share repurchase program.
Under our 2021 Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.

Item 6.    Exhibits
Exhibit Number
Exhibit Description
31.1
31.2
32.1
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

38

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vertex Pharmaceuticals Incorporated
October 28, 2022
By:
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Financial Officer
(principal financial officer and
duly authorized officer)

39
 EX-31.1 2 a2022q310-qexhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 28, 2022/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President


 EX-31.2 3 a2022q310-qexhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 28, 2022/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer

 EX-32.1 4 a2022q310-qexhibit321.htm EX-32.1 Document

Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: October 28, 2022
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President
Date: October 28, 2022
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer



 EX-101.SCH 5 vrtx-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Additional Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Acquired In-Process Research and Development and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Additional Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Collaborative Arrangement Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Business Combination - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Hedging - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Additional Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vrtx-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vrtx-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vrtx-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Matures within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] British pound sterling United Kingdom, Pounds Deferred tax assets Deferred Income Tax Assets, Net Entity Address, Postal Zip Code Entity Address, Postal Zip Code Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Unrealized holding losses on marketable securities, net Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Schedule of Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Fair Value of Our Contingent Consideration Liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Other non-cash items, net Other Noncash Income (Expense) Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Net income Net income Net income Net income Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Matures after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share Repurchase Program [Domain] Share Repurchase Program [Domain] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Equity Component [Domain] Equity Component [Domain] Discount Rate Measurement Input, Discount Rate [Member] Total financial assets Assets, Fair Value Disclosure Interest income Investment Income, Interest and Dividend Total stock-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Fair Value Debt securities Total Debt Securities, Available-for-Sale Hedging Designation [Domain] Hedging Designation [Domain] Other revenues Collaborative and Royalty [Member] Collaborative and Royalty [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] ESPP share issuances Employee Stock [Member] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Gross Amounts Presented Derivative Asset In Process Research and Development In Process Research and Development [Member] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Currencies [Domain] All Currencies [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] CRISPR A&R JDCA CRSIPR A&R JDCA [Member] CRISPR Amended and restated the Original CTX001 JDCA Legal Entity [Axis] Legal Entity [Axis] Total liabilities Liabilities Time deposits Bank Time Deposits [Member] Verve Verve [Member] Verve Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Other current liabilities, foreign currency forward contracts Derivative Liability, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Collaborative Arrangement Costs Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Australian dollar Australia, Dollars On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Purchase of common stock Payment To Acquire Common Stock Payment To Acquire Common Stock Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type SOFR Loan Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Financial instruments carried at fair value (asset positions): Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Asset Acquisition [Axis] Asset Acquisition [Axis] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] Document Period End Date Document Period End Date Deferred income taxes Increase (Decrease) in Other Deferred Liability Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Net income per common share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Fair Value Equity Securities, FV-NI, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued expenses Accrued Liabilities, Current Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Earnings Per Share Earnings Per Share [Text Block] Other long-term liabilities Other Noncurrent Liabilities [Member] Long-term finance lease liabilities Finance Lease, Liability, Noncurrent KALYDECO KALYDECO [Member] KALYDECO inventories, net Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Award Type [Domain] Award Type [Domain] Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Derivative Contract [Domain] Derivative Contract [Domain] ORKAMBI ORKAMBI [Member] ORKAMBI [Member] Entity Registrant Name Entity Registrant Name Foreign Currency Translation Adjustment Foreign Currency Forward Contract Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Entity Address, City or Town Entity Address, City or Town On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Up-front payment Collaborative Arrangement Up-front License Fee Collaborative Arrangement Up-front License Fee Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Collaborative arrangement costs Research and Development Expense Investment in equity securities and notes receivable Payment To Acquire Preferred Stock and Notes Receivable Payment To Acquire Preferred Stock and Notes Receivable Prepaid expenses and other current assets Restricted Cash and Cash Equivalents Restricted stock units (including PSUs) Unvested restricted stock units (including PSUs) Restricted Stock Units (RSUs) [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents: Fair Value Cash and Cash Equivalents, Fair Value Disclosure Business Combination Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Other Assets Other assets Other Assets [Member] Counterparty Name [Domain] Counterparty Name [Domain] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Allowance for credit loss for available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Government-sponsored enterprise securities Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Retained Earnings Retained Earnings [Member] Common Stock Common Stock [Member] Schedule of Stock-based Compensation Expense by Line Item Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total other comprehensive income Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Repurchases of common stock Payments for Repurchase of Common Stock Balance at December 31, 2021 Balance at September 30, 2022 Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Document Quarterly Report Document Quarterly Report Letters of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Additional Cash Flow Information Additional Financial Information Disclosure [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Additional Cash Flow Information Condensed Cash Flow Statement [Table Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Recurring Basis Fair Value, Recurring [Member] Net other assets Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Assets Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Assets Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Total collaborative arrangement costs included in costs and expenses Costs And Expenses [Member] Costs And Expenses Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement Statement [Line Items] Payments on finance leases Finance Lease, Principal Payments Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative expenses Selling, General and Administrative Expense Canadian dollar Canada, Dollars Change in fair value of contingent consideration Decrease in fair value of contingent consideration Decrease in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease assets Operating Lease, Right-of-Use Asset Product revenues, net Product [Member] Repurchase of common stock Value of shares repurchased Stock Repurchased During Period, Value Accumulated Other Comprehensive (Loss) Income Total AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Income from operations Operating Income (Loss) Inventories Increase (Decrease) in Inventories Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Effect of potentially dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Other current liabilities Other Current Liabilities [Member] Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Repurchase of common stock (in shares) Shares repurchased (in shares) Stock Repurchased During Period, Shares Indefinite-lived intangible assets Indefinite-Lived Intangible Assets Acquired Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cost of sales Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Gross Amounts Presented Derivative Liability Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Total liabilities Gross Amounts Recognized Derivative Liability, Subject to Master Netting Arrangement, before Offset Contingent liabilities Contingent Liabilities Contingent Liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Base Rate Base Rate [Member] Marketable securities: Marketable Securities Common stock, $0.01 par value; 500,000,000 shares authorized, 256,645,737 and 254,479,046 shares issued and outstanding, respectively Common Stock, Value, Issued Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Schedule of Potential Gross Common Equivalent Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Financial Assets Subject to Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Proceeds from finance leases Proceeds From Finance Leases Proceeds From Finance Leases Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash—beginning of period Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Foreign Currency Forward Contracts Foreign Exchange Forward [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Amendment Flag Amendment Flag Catalyst Biosciences Catalyst Biosciences [Member] Catalyst Biosciences Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised ViaCyte ViaCyte [Member] ViaCyte Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Other assets Other Assets, Noncurrent Unrealized gains (losses) on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Depreciation expense Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Cash equivalents: Cash and Cash Equivalents [Abstract] Currency [Axis] Currency [Axis] Stock options Stock options Share-Based Payment Arrangement, Option [Member] Other income (expense), net Other income (expense), net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Long-term contingent consideration Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Swiss Franc Switzerland, Francs Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax CRISPR CRISPR [Member] CRISPR Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Amortized Cost Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Designated as Hedging Instruments Designated as hedging instruments Designated as Hedging Instrument [Member] Cash paid for income taxes Income Taxes Paid, Net Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Unrealized gains on foreign currency forward contracts, net of tax of $(16.0), $(9.6), $(34.3) and $(21.2), respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Measurement Frequency [Domain] Measurement Frequency [Domain] Revenues: Revenues [Abstract] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Line of Credit Facility [Table] Line of Credit Facility [Table] Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Intangible asset Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Issuance of common stock under benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Income tax effect Share-Based Payment Arrangement, Expense, Tax Benefit Accounts receivable, net Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Share Repurchase Program 2020 Share Repurchase Program 2020 [Member] Share Repurchase Program 2020 Total costs and expenses Costs and Expenses Class of Treasury Stock [Table] Class of Treasury Stock [Table] Other assets, foreign currency forward contracts Derivative Asset, Noncurrent Business Combination and Asset Acquisition [Abstract] Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent U.S. Treasury securities US Treasury Securities [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Share Repurchase Program 2021 Share Repurchase Program 2021 [Member] Share Repurchase Program 2021 Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories Total Inventory, Net CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Accounts payable Accounts Payable, Current Allocation of net profits and net losses, percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain Amortized Cost Equity Securities, FV-NI, Cost Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Entity Filer Category Entity Filer Category Gross Amounts Offset Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Marketable securities Marketable Securities [Member] Marketable Securities [Member] Financial instruments carried at fair value (liability positions): Liabilities, Fair Value Disclosure [Abstract] Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Total stock-based compensation expense included in “Total costs and expenses” Share-Based Payment Arrangement, Expense Commitments and contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Notional amount of foreign currency forward contract Derivative, Notional Amount Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Restricted stock units (including PSUs) Restricted Stock [Member] TRIKAFTA/KAFTRIO TRIKAFTA/KAFTRIO [Member] TRIKAFTA/KAFTRIO [Member] Gross Amounts Not Offset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Revenues Revenue from Contract with Customer, Excluding Assessed Tax Cash equivalents: Cash and cash equivalents Cash and Cash Equivalents [Member] Cover [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Stock-based Compensation Expense and Share Repurchase Programs Share-Based Payment Arrangement [Text Block] Work-in-process Inventory, Work in Process, Net of Reserves Revenue Recognition Revenue from Contract with Customer [Text Block] Derivative asset current, foreign currency forward contracts Derivative Asset, Current Interest expense Interest Income (Expense), Net Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and shareholders’ equity Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Stock repurchase program, remaining amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Cash Cash Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Total product revenues outside of the United States Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Not Designated as Hedging Instrument Not designated as hedging instruments Not Designated as Hedging Instrument [Member] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Payment to acquire ViaCyte, Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Goodwill expected to be tax deductible Business Acquisition, Goodwill, Expected Tax Deductible Amount Current Fiscal Year End Date Current Fiscal Year End Date Marketable securities Marketable Securities, Current Intangible assets Intangible Assets, Net (Excluding Goodwill) Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Gross Amounts Not Offset Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Total stock-based compensation expense included in “Total costs and expenses” Share-Based Payment Arrangement, Expensed and Capitalized, Amount Other Other, Non U.S. [Member] Other, Non U.S. [Member] Corporate equity securities Equity Securities [Member] Net unrecognized tax benefits which would affect the tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Share Repurchase Program [Axis] Share Repurchase Program [Axis] Corporate debt securities Corporate Debt Securities [Member] Gross Amounts Offset Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Gains (losses) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Total assets Gross Amounts Recognized Derivative Asset, Subject to Master Netting Arrangement, before Offset Discrete tax benefit associated with an increase in U.K.'s corporate tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Entity Address, Address Line One Entity Address, Address Line One Other financing activities Proceeds from (Payments for) Other Financing Activities Stock-based compensation expense related to inventories Share-Based Payment Arrangement, Amount Capitalized Contract liabilities Contract with Customer, Liability Net unrealized gains (losses) Unrealized Gain (Loss) on Investments Impairment of intangible assets Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Product and Service [Axis] Product and Service [Axis] Europe Europe [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Total marketable debt securities Debt Securities, Available-for-Sale [Abstract] Credit Facility [Axis] Credit Facility [Axis] Inventories Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Common stock withheld for employee tax obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Contingent consideration, measurement input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Indefinite-Lived Intangible Assets [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Common stock withheld for employee tax obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Acquired In-Process Research and Development and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Total purchase price Business Combination, Consideration Transferred Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Measurement Input Type [Axis] Measurement Input Type [Axis] Entity [Domain] Entity [Domain] City Area Code City Area Code Assets Assets [Abstract] Collaborative arrangement, right to exclusively license, number of targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Euro Euro Member Countries, Euro Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Maturities of available-for-sale debt securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Acquired in-process research and development expenses Research and Development in Process Total financial liabilities Financial Liabilities Fair Value Disclosure Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Other long-term liabilities Other Liabilities, Noncurrent Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development expenses Research and Development Expense [Member] Derivative term Derivative, Term of Contract Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Sales [Member] Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Other long-term liabilities, foreign currency forward contracts Derivative Liability, Noncurrent EX-101.PRE 9 vrtx-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 vrtx-20220930_g1.gif begin 644 vrtx-20220930_g1.gif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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 9 Months Ended
Sep. 30, 2022
Oct. 21, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 000-19319  
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-3039129  
Entity Address, Address Line One 50 Northern Avenue  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 617  
Local Phone Number 341-6100  
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share  
Trading Symbol VRTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   256,691,452
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  

XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Revenues $ 2,334.3 $ 1,984.1 $ 6,628.0 $ 5,501.8
Costs and expenses:        
Cost of sales 289.4 236.5 797.0 656.8
Research and development expenses 645.0 467.0 1,846.2 1,370.0
Acquired in-process research and development expenses 29.0 26.7 92.9 986.8
Selling, general and administrative expenses 246.8 198.2 677.3 584.9
Change in fair value of contingent consideration (2.6) 1.2 (59.3) (1.1)
Total costs and expenses 1,207.6 929.6 3,354.1 3,597.4
Income from operations 1,126.7 1,054.5 3,273.9 1,904.4
Interest income 46.2 1.1 58.6 3.7
Interest expense (13.7) (15.2) (43.2) (46.4)
Other income (expense), net 17.2 42.4 (133.7) (2.2)
Income before provision for income taxes 1,176.4 1,082.8 3,155.6 1,859.5
Provision for income taxes 245.9 230.9 652.5 287.5
Net income $ 930.5 $ 851.9 $ 2,503.1 $ 1,572.0
Net income per common share:        
Basic (in dollars per share) $ 3.63 $ 3.30 $ 9.78 $ 6.08
Diluted (in dollars per share) $ 3.59 $ 3.28 $ 9.68 $ 6.03
Shares used in per share calculations:        
Basic (in shares) 256.5 257.9 255.8 258.7
Diluted (in shares) 259.5 259.7 258.7 260.9
Product revenues, net        
Revenues:        
Revenues $ 2,334.3 $ 1,984.1 $ 6,628.0 $ 5,500.8
Other revenues        
Revenues:        
Revenues $ 0.0 $ 0.0 $ 0.0 $ 1.0
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income $ 930.5 $ 851.9 $ 2,503.1 $ 1,572.0
Other comprehensive income:        
Unrealized holding losses on marketable securities, net (0.6) (0.0) (3.6) (0.3)
Unrealized gains on foreign currency forward contracts, net of tax of $(16.0), $(9.6), $(34.3) and $(21.2), respectively 58.8 34.7 128.1 77.0
Foreign currency translation adjustment (18.1) 2.0 (42.8) 3.3
Total other comprehensive income 40.1 36.7 81.7 80.0
Comprehensive income $ 970.6 $ 888.6 $ 2,584.8 $ 1,652.0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Unrealized gains (losses) on foreign currency forward contracts, tax $ (16.0) $ (9.6) $ (34.3) $ (21.2)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 9,171.5 $ 6,795.0
Marketable securities 599.2 729.9
Accounts receivable, net 1,385.2 1,136.8
Inventories 388.2 353.1
Prepaid expenses and other current assets 726.9 545.8
Total current assets 12,271.0 9,560.6
Property and equipment, net 1,118.7 1,094.1
Goodwill 1,075.2 1,002.2
Intangible assets 603.6 400.0
Deferred tax assets 1,162.7 934.5
Operating lease assets 342.7 330.3
Other assets 132.5 110.8
Total assets 16,706.4 13,432.5
Current liabilities:    
Accounts payable 126.9 195.0
Accrued expenses 2,264.4 1,678.6
Other current liabilities 218.0 268.4
Total current liabilities 2,609.3 2,142.0
Long-term finance lease liabilities 442.3 509.8
Long-term operating lease liabilities 382.3 377.4
Long-term contingent consideration 127.2 186.5
Other long-term liabilities 115.7 116.8
Total liabilities 3,676.8 3,332.5
Commitments and contingencies 0.0 0.0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0.0 0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 256,645,737 and 254,479,046 shares issued and outstanding, respectively 2.6 2.5
Additional paid-in capital 7,225.5 6,880.8
Accumulated other comprehensive income 97.6 15.9
Retained earnings 5,703.9 3,200.8
Total shareholders’ equity 13,029.6 10,100.0
Total liabilities and shareholders’ equity $ 16,706.4 $ 13,432.5
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 256,645,737 254,479,046
Common stock, shares outstanding (in shares) 256,645,737 254,479,046
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2020   259.9      
Beginning balance at Dec. 31, 2020 $ 8,686.8 $ 2.6 $ 7,894.0 $ (68.5) $ 858.7
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income, net of tax 80.0     80.0  
Net income 1,572.0       1,572.0
Repurchase of common stock (in shares)   (5.3)      
Repurchase of common stock (1,067.2) $ (0.0) (1,067.2)    
Common stock withheld for employee tax obligations (in shares)   (0.6)      
Common stock withheld for employee tax obligations (134.2) $ (0.0) (134.2)    
Issuance of common stock under benefit plans (in shares)   2.2      
Issuance of common stock under benefit plans 66.8 $ 0.0 66.8    
Stock-based compensation expense 326.6   326.6    
Ending balance (in shares) at Sep. 30, 2021   256.2      
Ending balance at Sep. 30, 2021 9,530.8 $ 2.6 7,086.0 11.5 2,430.7
Beginning balance (in shares) at Jun. 30, 2021   259.1      
Beginning balance at Jun. 30, 2021 9,196.4 $ 2.6 7,640.2 (25.2) 1,578.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income, net of tax 36.7     36.7  
Net income 851.9       851.9
Repurchase of common stock (in shares)   (3.3)      
Repurchase of common stock (642.2) $ (0.0) (642.2)    
Common stock withheld for employee tax obligations (in shares)   (0.1)      
Common stock withheld for employee tax obligations (28.6) $ (0.0) (28.6)    
Issuance of common stock under benefit plans (in shares)   0.5      
Issuance of common stock under benefit plans 12.9 $ 0.0 12.9    
Stock-based compensation expense 103.7   103.7    
Ending balance (in shares) at Sep. 30, 2021   256.2      
Ending balance at Sep. 30, 2021 9,530.8 $ 2.6 7,086.0 11.5 2,430.7
Beginning balance (in shares) at Dec. 31, 2021   254.5      
Beginning balance at Dec. 31, 2021 10,100.0 $ 2.5 6,880.8 15.9 3,200.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income, net of tax 81.7     81.7  
Net income 2,503.1       2,503.1
Common stock withheld for employee tax obligations (in shares)   (0.7)      
Common stock withheld for employee tax obligations (169.9) $ (0.0) (169.9)    
Issuance of common stock under benefit plans (in shares)   2.8      
Issuance of common stock under benefit plans 135.3 $ 0.1 135.2    
Stock-based compensation expense 379.4   379.4    
Ending balance (in shares) at Sep. 30, 2022   256.6      
Ending balance at Sep. 30, 2022 13,029.6 $ 2.6 7,225.5 97.6 5,703.9
Beginning balance (in shares) at Jun. 30, 2022   256.0      
Beginning balance at Jun. 30, 2022 11,933.5 $ 2.6 7,100.0 57.5 4,773.4
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income, net of tax 40.1     40.1  
Net income 930.5       930.5
Common stock withheld for employee tax obligations (in shares)   (0.2)      
Common stock withheld for employee tax obligations (48.0) $ (0.0) (48.0)    
Issuance of common stock under benefit plans (in shares)   0.8      
Issuance of common stock under benefit plans 38.2 $ 0.0 38.2    
Stock-based compensation expense 135.3   135.3    
Ending balance (in shares) at Sep. 30, 2022   256.6      
Ending balance at Sep. 30, 2022 $ 13,029.6 $ 2.6 $ 7,225.5 $ 97.6 $ 5,703.9
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net income $ 2,503.1 $ 1,572.0
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 379.8 322.8
Depreciation expense 109.9 91.8
Decrease in fair value of contingent consideration (59.3) (1.1)
Deferred income taxes (424.0) (112.7)
Gains (losses) on equity securities 143.1 (5.0)
Other non-cash items, net (32.8) 20.5
Changes in operating assets and liabilities:    
Accounts receivable, net (368.8) (231.2)
Inventories (58.1) (65.8)
Prepaid expenses and other assets (41.9) (107.7)
Accounts payable (39.1) (22.0)
Accrued expenses 980.3 254.2
Other liabilities (40.7) (67.3)
Net cash provided by operating activities 3,051.5 1,648.5
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (417.8) (447.8)
Maturities of available-for-sale debt securities 435.9 452.1
Payment to acquire ViaCyte, Inc., net of cash acquired (295.9) 0.0
Purchases of property and equipment (171.1) (173.2)
Investment in equity securities and notes receivable (47.8) (38.0)
Net cash used in investing activities (496.7) (206.9)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 134.7 67.3
Repurchases of common stock 0.0 (1,057.2)
Payments in connection with common stock withheld for employee tax obligations (169.9) (134.2)
Payments on finance leases (75.1) (34.6)
Proceeds from finance leases 0.0 12.6
Other financing activities 2.4 4.3
Net cash used in financing activities (107.9) (1,141.8)
Effect of changes in exchange rates on cash (70.0) (8.5)
Net increase in cash, cash equivalents and restricted cash 2,376.9 291.3
Cash, cash equivalents and restricted cash—beginning of period 6,800.1 5,988.9
Cash, cash equivalents and restricted cash—end of period 9,177.0 6,280.2
Supplemental disclosure of cash flow information:    
Cash paid for interest 41.1 42.7
Cash paid for income taxes $ 840.1 $ 381.5
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of operations. To conform prior periods to current presentation, we reclassified $26.7 million and $986.8 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and nine months ended September 30, 2021, respectively. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
TRIKAFTA/KAFTRIO$2,010.5 $1,555.8 $5,665.3 $4,004.6 
SYMDEKO/SYMKEVI38.2 81.4 145.7 340.0 
ORKAMBI146.2 184.5 399.9 624.2 
KALYDECO139.4 162.4 417.1 532.0 
Total product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Product Revenues by Geographic Location
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
United States$1,455.6 $1,382.9 $4,238.9 $3,893.2 
Outside of the United States
Europe730.5 518.8 2,018.3 1,382.7 
Other
148.2 82.4 370.8 224.9 
Total product revenues outside of the United States878.7 601.2 2,389.1 1,607.6 
Total product revenues, net
$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Contract Liabilities
We had contract liabilities of $119.5 million and $171.7 million as of September 30, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquired In-Process Research and Development and Other Arrangements
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Acquired In-Process Research and Development and Other Arrangements Acquired In-Process Research and Development and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $29.0 million and $92.9 million for the three and nine months ended September 30, 2022, respectively, and $26.7 million and $986.8 million, for the three and nine months ended September 30, 2021, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three and nine months ended September 30, 2022 and 2021, or were new or materially revised during the three and nine months ended September 30, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), formerly known as CTX001, for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we lead global development, manufacturing and commercialization of exa-cel, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including exa-cel) throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Acquired in-process research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to exa-cel pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, subject to certain adjustments, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three and nine months ended September 30, 2022 and 2021, we recognized the following amounts in total, not including amounts recorded to “Acquired in-process research and development expenses,” related to these agreements:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Total expenses incurred under the Original CTX001 JDCA and A&R JDCA$98.2 $58.7 $259.8 $147.4 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
$59.0 $35.2 $155.9 $79.6 
Verve Therapeutics, Inc.
In July 2022, we entered into a research collaboration with Verve Therapeutics, Inc. (“Verve”) focused on discovering and developing an in vivo gene-editing program for a liver disease. Under the terms of the agreement, we made a $25.0 million upfront payment to Verve and purchased $35.0 million of Verve’s common stock. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” The investment in Verve’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”
Asset Acquisition
Catalyst Biosciences, Inc. - Complement 3 Degrader Program
In May 2022, pursuant to an asset purchase agreement, we acquired Catalyst Biosciences, Inc.’s portfolio of protease medicines that target the complement system (the “complement portfolio”) and related intellectual property, including CB 2782-PEG, which is a pre-clinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration. We determined that substantially all the fair value acquired was concentrated in the CB-2782 PEG in-process research and development assets, which did not constitute a business, and for which we determined there was no alternative future use. As a result, we recorded our $60.0 million upfront payment to “Acquired in-process research and development expenses” in the nine months ended September 30, 2022.
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combination
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Business Combination Business Combination
On September 27, 2022, we acquired all outstanding shares of ViaCyte, Inc. (“ViaCyte”), a privately held biotechnology company primarily focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, in exchange for $315.0 million. ViaCyte’s intellectual property and assembled workforce complement our ongoing programs and have the potential to produce therapies for patients with type 1 diabetes. We accounted for the transaction as a business combination, and allocated the purchase price to the following assets acquired and liabilities assumed:
As of September 27, 2022
(in millions)
Cash and cash equivalents$19.1 
Goodwill73.0 
Intangible asset216.6 
Net other assets
6.3 
Total purchase price
$315.0 
The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets acquired and liabilities assumed. The goodwill is attributable to (i) the technological expertise in cell therapy of ViaCyte’s assembled workforce, (ii) the potential synergies from combining ViaCyte’s technology with our clinical development capabilities and (iii) the potential future benefits for other therapeutic programs that the acquired technology could be used for, but did not meet the definition of an in-process research and development asset. None of the goodwill is expected to be deductible for income tax purposes.
The “Intangible asset” is an in-process research and development asset of $216.6 million related to ViaCyte’s technology and intellectual property associated with stem cell differentiation and manufacturing. The fair value of the intangible asset was determined through a discounted cash flow analysis using the relief from royalty method, which estimated the cost savings associated with owning an asset instead of paying a royalty to the previous owner. The relief from royalty method utilized Level 3 fair value inputs including (i) estimated future product sales, which were calculated using, among other assumptions, an estimated probability of obtaining marketing approval for the asset, (ii) estimated after-tax royalty savings expected from ownership of the asset, and (iii) an appropriate discount and tax rate.
As of September 30, 2022, our analysis of the fair value of certain assets acquired, including certain tax analyses, related to the ViaCyte business combination is preliminary and will be finalized during the measurement period of up to one year from the acquisition date. The financial results of ViaCyte did not have a material effect on our condensed consolidated statement of operations in the three and nine months ended September 30, 2022
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions, except per share amounts)
Net income$930.5 $851.9 $2,503.1 $1,572.0 
Basic weighted-average common shares outstanding256.5 257.9 255.8 258.7 
Effect of potentially dilutive securities:
Stock options1.4 1.0 1.4 1.1 
Restricted stock units (including PSUs)
1.6 0.8 1.4 1.1 
Employee stock purchase program
0.0 0.0 0.1 0.0 
Diluted weighted-average common shares outstanding259.5 259.7 258.7 260.9 
Basic net income per common share$3.63 $3.30 $9.78 $6.08 
Diluted net income per common share$3.59 $3.28 $9.68 $6.03 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Stock options— 1.1 0.0 0.7 
Unvested restricted stock units (including PSUs)0.0 0.2 0.2 0.4 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note G, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively):
As of September 30, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$3,610.9 $3,610.9 $— $— $3,478.1 $3,478.1 $— $— 
Time deposits2,000.0 — 2,000.0 — — — — — 
Commercial paper18.2 — 18.2 — — — — — 
Marketable securities:
Corporate equity securities122.8 78.2 44.6 — 230.9 230.9 — — 
U.S. Treasury securities130.0 130.0 — — 86.4 86.4 — — 
Government-sponsored enterprise securities
10.5 10.5 — — 69.0 69.0 — — 
Corporate debt securities
66.8 — 66.8 — 90.9 — 90.9 — 
Commercial paper
269.1 — 269.1 — 252.7 — 252.7 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts191.6 — 191.6 — 44.5 — 44.5 — 
Other assets:
Foreign currency forward contracts9.1 — 9.1 — 2.0 — 2.0 — 
Total financial assets
$6,429.0 $3,829.6 $2,599.4 $— $4,254.5 $3,864.4 $390.1 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(0.0)$— $(0.0)$— $(5.6)$— $(5.6)$— 
Long-term contingent consideration
(127.2)— — (127.2)(186.5)— — (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(0.0)— (0.0)— (2.7)— (2.7)— 
Total financial liabilities
$(127.2)$— $(0.0)$(127.2)$(194.8)$— $(8.3)$(186.5)
Please refer to Note G, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note G, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy and other severe neuromuscular diseases, including myotonic dystrophy type 1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.2% and 5.7% as of September 30, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and
commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Nine Months Ended September 30, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(59.3)
Balance at September 30, 2022$127.2 
The decrease in fair value of contingent consideration during the nine months ended September 30, 2022 was primarily due to a revision to the scope of certain acquired gene-editing programs in the second quarter of 2022.
Fair Value of Intangible Assets
As of September 30, 2022 and December 31, 2021, we had $603.6 million and $400.0 million, respectively, of in-process research and development intangible assets classified as “Intangible assets” on our condensed consolidated balance sheets. In the third quarter of 2022, we recorded a $216.6 million in-process research and development intangible asset resulting from our acquisition of ViaCyte, which is described in Note D, “Business Combination.” In the nine months ended September 30, 2022, we recorded a $13.0 million impairment of an in-process research and development intangible asset to “Research and development expenses,” due to a decision to revise the scope of certain acquired gene-editing programs.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities and Equity Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively), is shown below:
As of September 30, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$3,610.9 $— $— $3,610.9 $3,478.1 $— $— $3,478.1 
Time deposits2,000.0 — — 2,000.0 — — — — 
Commercial paper18.2 — — 18.2 — — — — 
Total cash equivalents
$5,629.1 $— $— $5,629.1 $3,478.1 $— $— $3,478.1 
Marketable securities:
U.S. Treasury securities$131.7 $— $(1.7)$130.0 $86.6 $— $(0.2)$86.4 
Government-sponsored enterprise securities
10.6 — (0.1)10.5 69.0 — — 69.0 
Corporate debt securities
67.8 — (1.0)66.8 91.1 — (0.2)90.9 
Commercial paper
270.4 — (1.3)269.1 252.8 — (0.1)252.7 
Total marketable debt securities
480.5 — (4.1)476.4 499.5 — (0.5)499.0 
Corporate equity securities
104.4 29.2 (10.8)122.8 69.4 167.1 (5.6)230.9 
Total marketable securities
$584.9 $29.2 $(14.9)$599.2 $568.9 $167.1 $(6.1)$729.9 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of September 30, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$3,629.1 $3,478.1 
Marketable securities
476.4 499.0 
Total
$4,105.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of September 30, 2022As of December 31, 2021
(in millions)
Matures within one year$4,091.4 $3,912.3 
Matures after one year through five years
14.1 64.8 
Total
$4,105.5 $3,977.1 
We have a limited number of available-for-sale debt securities in insignificant loss positions as of September 30, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three and nine months ended September 30, 2022 and 2021.
We record changes in the fair value of our investments in corporate equity securities to “Other income (expense), net” in our condensed consolidated statements of operations. During the three and nine months ended September 30, 2022 and 2021, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Net unrealized gains (losses)
$16.7 $46.7 $(143.1)$5.0 
        
As of September 30, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(42.8)(3.6)230.2 183.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (102.1)(102.1)
Net current period other comprehensive (loss) income(42.8)(3.6)128.1 81.7 
Balance at September 30, 2022$(56.4)$(4.1)$158.1 $97.6 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications3.3 (0.3)46.2 49.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — 30.8 30.8 
Net current period other comprehensive income (loss)3.3 (0.3)77.0 80.0 
Balance at September 30, 2021$(12.3)$0.0 $23.8 $11.5 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2022, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of September 30, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of September 30, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,081.9 $1,364.5 
Canadian dollar
192.3 89.9 
British pound sterling
183.5 287.7 
Australian dollar
150.8 96.3 
Swiss Franc59.2 54.1 
Total foreign currency forward contracts
$1,667.7 $1,892.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income (expense), net” in our condensed consolidated statements of operations each period. As of September 30, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $641.6 million.
During the three and nine months ended September 30, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$65.2 $(5.2)$130.3 $(39.3)
Not designated as hedging instruments
Other income (expense), net$(22.1)$(0.4)$(38.9)$(9.4)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Other income (expense), net$17.2 $42.4 $(133.7)$(2.2)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of September 30, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$191.6 Other current liabilities$(0.0)
Other assets9.1 Other long-term liabilities(0.0)
Total assets
$200.7 
Total liabilities
$(0.0)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of September 30, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of September 30, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$200.7 $— $200.7 $(0.0)$200.7 
Total liabilities(0.0)— (0.0)0.0 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
As of September 30, 2022As of December 31, 2021
(in millions)
Raw materials$32.2 $42.4 
Work-in-process229.3 224.0 
Finished goods
126.7 86.7 
Total
$388.2 $353.1 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation Expense and Share Repurchase Programs
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Share Repurchase Programs Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three and nine months ended September 30, 2022 and 2021, we recognized the following stock-based compensation expense:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$130.3 $89.5 $351.5 $279.1 
Stock options3.1 7.9 14.9 29.6 
ESPP share issuances1.9 6.3 13.0 17.9 
Stock-based compensation expense related to inventories
0.3 (0.7)0.4 (3.8)
Total stock-based compensation expense included in “Total costs and expenses”
$135.6 $103.0 $379.8 $322.8 
Stock-based compensation expense by line item:
Cost of sales$2.4 $1.6 $7.0 $4.6 
Research and development expenses80.0 61.0 229.9 196.4 
Selling, general and administrative expenses53.2 40.4 142.9 121.8 
Total stock-based compensation expense included in costs and expenses
135.6 103.0 379.8 322.8 
Income tax effect(38.8)(21.6)(101.3)(73.7)
Total stock-based compensation expense, net of tax
$96.8 $81.4 $278.5 $249.1 
Share repurchase programs
In November 2020, our Board of Directors approved a share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and the first quarter of 2021. During the three months ended March 31, 2021, we repurchased 2.0 million shares of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million.
In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the nine months ended September 30, 2022, we did not repurchase any shares of our common stock under the 2021 Share Repurchase Program. As of September 30, 2022, a total of $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three and nine months ended September 30, 2022 and 2021, we recorded the following provisions for (benefits from) income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions, except percentages)
Income before provision for income taxes$1,176.4 $1,082.8 $3,155.6 $1,859.5 
Provision for income taxes245.9 230.9 652.5 287.5 
Effective tax rate21 %21 %21 %15 %
Our effective tax rate for the three and nine months ended September 30, 2022, and the three months ended September 30, 2021, was similar to the U.S. statutory rate.
Our effective tax rate for the nine months ended September 30, 2021 was different than the U.S. statutory rate primarily due to a $99.7 million discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2022 and December 31, 2021, we had $144.9 million and $129.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
Starting in 2022, our cash paid for income taxes is substantially increasing due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Jobs Act of 2017, amortize them over a five year period if they are performed in the U.S. and fifteen years if they are performed in foreign jurisdictions.
In August 2022, the Inflation Reduction Act of 2022 (“IRA”) was enacted into law. The IRA includes a 15% corporate alternative minimum tax and a 1% excise tax on share repurchases. We do not expect the IRA to have a significant impact on our consolidated financial statements.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018 in jurisdictions that have a material impact on our consolidated financial statements.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a SOFR rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of September 30, 2022, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Prior Credit Facilities
In July 2022, in conjunction with entering our new credit agreement, we terminated the $500.0 million credit agreement we entered into in 2019. In September 2022, a $2.0 billion credit agreement we entered into in 2020 expired in accordance with its terms.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note F, “Fair Value Measurements,” there were no material contingent liabilities accrued as of September 30, 2022 or December 31, 2021.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Additional Cash Flow Information
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Additional Cash Flow Information Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Nine Months Ended September 30,
20222021
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$6,795.0 $9,171.5 $5,988.2 $6,275.7 
Prepaid expenses and other current assets
5.1 5.5 0.7 4.5 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$6,800.1 $9,177.0 $5,988.9 $6,280.2 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of operations. To conform prior periods to current presentation, we reclassified $26.7 million and $986.8 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and nine months ended September 30, 2021, respectively. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Product revenues, net consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
TRIKAFTA/KAFTRIO$2,010.5 $1,555.8 $5,665.3 $4,004.6 
SYMDEKO/SYMKEVI38.2 81.4 145.7 340.0 
ORKAMBI146.2 184.5 399.9 624.2 
KALYDECO139.4 162.4 417.1 532.0 
Total product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
United States$1,455.6 $1,382.9 $4,238.9 $3,893.2 
Outside of the United States
Europe730.5 518.8 2,018.3 1,382.7 
Other
148.2 82.4 370.8 224.9 
Total product revenues outside of the United States878.7 601.2 2,389.1 1,607.6 
Total product revenues, net
$2,334.3 $1,984.1 $6,628.0 $5,500.8 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquired In-Process Research and Development and Other Arrangements (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Arrangement Costs During the three and nine months ended September 30, 2022 and 2021, we recognized the following amounts in total, not including amounts recorded to “Acquired in-process research and development expenses,” related to these agreements:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Total expenses incurred under the Original CTX001 JDCA and A&R JDCA$98.2 $58.7 $259.8 $147.4 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
$59.0 $35.2 $155.9 $79.6 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combination (Tables)
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed We accounted for the transaction as a business combination, and allocated the purchase price to the following assets acquired and liabilities assumed:
As of September 27, 2022
(in millions)
Cash and cash equivalents$19.1 
Goodwill73.0 
Intangible asset216.6 
Net other assets
6.3 
Total purchase price
$315.0 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions, except per share amounts)
Net income$930.5 $851.9 $2,503.1 $1,572.0 
Basic weighted-average common shares outstanding256.5 257.9 255.8 258.7 
Effect of potentially dilutive securities:
Stock options1.4 1.0 1.4 1.1 
Restricted stock units (including PSUs)
1.6 0.8 1.4 1.1 
Employee stock purchase program
0.0 0.0 0.1 0.0 
Diluted weighted-average common shares outstanding259.5 259.7 258.7 260.9 
Basic net income per common share$3.63 $3.30 $9.78 $6.08 
Diluted net income per common share$3.59 $3.28 $9.68 $6.03 
Schedule of Potential Gross Common Equivalent Shares
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Stock options— 1.1 0.0 0.7 
Unvested restricted stock units (including PSUs)0.0 0.2 0.2 0.4 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Subject to Fair Value Measurements
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively):
As of September 30, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$3,610.9 $3,610.9 $— $— $3,478.1 $3,478.1 $— $— 
Time deposits2,000.0 — 2,000.0 — — — — — 
Commercial paper18.2 — 18.2 — — — — — 
Marketable securities:
Corporate equity securities122.8 78.2 44.6 — 230.9 230.9 — — 
U.S. Treasury securities130.0 130.0 — — 86.4 86.4 — — 
Government-sponsored enterprise securities
10.5 10.5 — — 69.0 69.0 — — 
Corporate debt securities
66.8 — 66.8 — 90.9 — 90.9 — 
Commercial paper
269.1 — 269.1 — 252.7 — 252.7 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts191.6 — 191.6 — 44.5 — 44.5 — 
Other assets:
Foreign currency forward contracts9.1 — 9.1 — 2.0 — 2.0 — 
Total financial assets
$6,429.0 $3,829.6 $2,599.4 $— $4,254.5 $3,864.4 $390.1 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(0.0)$— $(0.0)$— $(5.6)$— $(5.6)$— 
Long-term contingent consideration
(127.2)— — (127.2)(186.5)— — (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(0.0)— (0.0)— (2.7)— (2.7)— 
Total financial liabilities
$(127.2)$— $(0.0)$(127.2)$(194.8)$— $(8.3)$(186.5)
Schedule of Fair Value of Our Contingent Consideration Liabilities
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Nine Months Ended September 30, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(59.3)
Balance at September 30, 2022$127.2 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities and Equity Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Equivalents and Marketable Securities
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively), is shown below:
As of September 30, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$3,610.9 $— $— $3,610.9 $3,478.1 $— $— $3,478.1 
Time deposits2,000.0 — — 2,000.0 — — — — 
Commercial paper18.2 — — 18.2 — — — — 
Total cash equivalents
$5,629.1 $— $— $5,629.1 $3,478.1 $— $— $3,478.1 
Marketable securities:
U.S. Treasury securities$131.7 $— $(1.7)$130.0 $86.6 $— $(0.2)$86.4 
Government-sponsored enterprise securities
10.6 — (0.1)10.5 69.0 — — 69.0 
Corporate debt securities
67.8 — (1.0)66.8 91.1 — (0.2)90.9 
Commercial paper
270.4 — (1.3)269.1 252.8 — (0.1)252.7 
Total marketable debt securities
480.5 — (4.1)476.4 499.5 — (0.5)499.0 
Corporate equity securities
104.4 29.2 (10.8)122.8 69.4 167.1 (5.6)230.9 
Total marketable securities
$584.9 $29.2 $(14.9)$599.2 $568.9 $167.1 $(6.1)$729.9 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of September 30, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$3,629.1 $3,478.1 
Marketable securities
476.4 499.0 
Total
$4,105.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of September 30, 2022As of December 31, 2021
(in millions)
Matures within one year$4,091.4 $3,912.3 
Matures after one year through five years
14.1 64.8 
Total
$4,105.5 $3,977.1 
Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities During the three and nine months ended September 30, 2022 and 2021, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Net unrealized gains (losses)
$16.7 $46.7 $(143.1)$5.0 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(42.8)(3.6)230.2 183.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (102.1)(102.1)
Net current period other comprehensive (loss) income(42.8)(3.6)128.1 81.7 
Balance at September 30, 2022$(56.4)$(4.1)$158.1 $97.6 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications3.3 (0.3)46.2 49.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — 30.8 30.8 
Net current period other comprehensive income (loss)3.3 (0.3)77.0 80.0 
Balance at September 30, 2021$(12.3)$0.0 $23.8 $11.5 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging (Tables)
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of September 30, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,081.9 $1,364.5 
Canadian dollar
192.3 89.9 
British pound sterling
183.5 287.7 
Australian dollar
150.8 96.3 
Swiss Franc59.2 54.1 
Total foreign currency forward contracts
$1,667.7 $1,892.5 
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three and nine months ended September 30, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$65.2 $(5.2)$130.3 $(39.3)
Not designated as hedging instruments
Other income (expense), net$(22.1)$(0.4)$(38.9)$(9.4)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,334.3 $1,984.1 $6,628.0 $5,500.8 
Other income (expense), net$17.2 $42.4 $(133.7)$(2.2)
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of September 30, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$191.6 Other current liabilities$(0.0)
Other assets9.1 Other long-term liabilities(0.0)
Total assets
$200.7 
Total liabilities
$(0.0)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
Schedule of Offsetting Liabilities The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of September 30, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$200.7 $— $200.7 $(0.0)$200.7 
Total liabilities(0.0)— (0.0)0.0 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
Schedule of Offsetting Assets The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of September 30, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$200.7 $— $200.7 $(0.0)$200.7 
Total liabilities(0.0)— (0.0)0.0 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
As of September 30, 2022As of December 31, 2021
(in millions)
Raw materials$32.2 $42.4 
Work-in-process229.3 224.0 
Finished goods
126.7 86.7 
Total
$388.2 $353.1 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation Expense and Share Repurchase Programs (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense by Line Item
During the three and nine months ended September 30, 2022 and 2021, we recognized the following stock-based compensation expense:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$130.3 $89.5 $351.5 $279.1 
Stock options3.1 7.9 14.9 29.6 
ESPP share issuances1.9 6.3 13.0 17.9 
Stock-based compensation expense related to inventories
0.3 (0.7)0.4 (3.8)
Total stock-based compensation expense included in “Total costs and expenses”
$135.6 $103.0 $379.8 $322.8 
Stock-based compensation expense by line item:
Cost of sales$2.4 $1.6 $7.0 $4.6 
Research and development expenses80.0 61.0 229.9 196.4 
Selling, general and administrative expenses53.2 40.4 142.9 121.8 
Total stock-based compensation expense included in costs and expenses
135.6 103.0 379.8 322.8 
Income tax effect(38.8)(21.6)(101.3)(73.7)
Total stock-based compensation expense, net of tax
$96.8 $81.4 $278.5 $249.1 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates During the three and nine months ended September 30, 2022 and 2021, we recorded the following provisions for (benefits from) income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
(in millions, except percentages)
Income before provision for income taxes$1,176.4 $1,082.8 $3,155.6 $1,859.5 
Provision for income taxes245.9 230.9 652.5 287.5 
Effective tax rate21 %21 %21 %15 %
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Additional Cash Flow Information (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Nine Months Ended September 30,
20222021
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$6,795.0 $9,171.5 $5,988.2 $6,275.7 
Prepaid expenses and other current assets
5.1 5.5 0.7 4.5 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$6,800.1 $9,177.0 $5,988.9 $6,280.2 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Accounting Policies (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Accounting Policies [Abstract]        
Number of operating segments | segment     1  
Acquired in-process research and development expenses | $ $ 29.0 $ 26.7 $ 92.9 $ 986.8
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Revenues $ 2,334.3 $ 1,984.1 $ 6,628.0 $ 5,501.8
United States        
Disaggregation of Revenue [Line Items]        
Revenues 1,455.6 1,382.9 4,238.9 3,893.2
Europe        
Disaggregation of Revenue [Line Items]        
Revenues 730.5 518.8 2,018.3 1,382.7
Other        
Disaggregation of Revenue [Line Items]        
Revenues 148.2 82.4 370.8 224.9
Total product revenues outside of the United States        
Disaggregation of Revenue [Line Items]        
Revenues 878.7 601.2 2,389.1 1,607.6
Product revenues, net        
Disaggregation of Revenue [Line Items]        
Revenues 2,334.3 1,984.1 6,628.0 5,500.8
TRIKAFTA/KAFTRIO        
Disaggregation of Revenue [Line Items]        
Revenues 2,010.5 1,555.8 5,665.3 4,004.6
SYMDEKO/SYMKEVI        
Disaggregation of Revenue [Line Items]        
Revenues 38.2 81.4 145.7 340.0
ORKAMBI        
Disaggregation of Revenue [Line Items]        
Revenues 146.2 184.5 399.9 624.2
KALYDECO        
Disaggregation of Revenue [Line Items]        
Revenues $ 139.4 $ 162.4 $ 417.1 $ 532.0
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Additional Information (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Contract liabilities $ 119.5 $ 171.7
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2019
USD ($)
target
Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Acquired in-process research and development expenses     $ 29,000,000.0 $ 26,700,000   $ 92,900,000 $ 986,800,000    
Verve                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Up-front payment $ 25,000,000                
Purchase of common stock $ 35,000,000                
Catalyst Biosciences                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Asset acquisition, consideration transferred   $ 60,000,000              
CRISPR Therapeutics                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Collaborative arrangement, right to exclusively license, number of targets | target               3  
Collaborative arrangement, development and regulatory potential milestone payments maximum               $ 410,000,000  
CRISPR A&R JDCA                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Collaborative arrangement, development and regulatory potential milestone payments maximum         $ 200,000,000        
Up-front payment         $ 900,000,000        
Allocation of net profits and net losses, percent                 60.00%
CRISPR A&R JDCA | CRISPR                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Allocation of net profits and net losses, percent                 40.00%
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquired In-Process Research and Development and Other Arrangements - Collaborative Arrangement Costs (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement - CRISPR Therapeutics - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative arrangement costs $ 98.2 $ 58.7 $ 259.8 $ 147.4
Total collaborative arrangement costs included in costs and expenses        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative arrangement costs $ 59.0 $ 35.2 $ 155.9 $ 79.6
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combination - Additional Information (Details) - ViaCyte
Sep. 27, 2022
USD ($)
Business Acquisition [Line Items]  
Total purchase price $ 315,000,000
Goodwill expected to be tax deductible 0
In Process Research and Development  
Business Acquisition [Line Items]  
Intangible asset $ 216,600,000
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Sep. 27, 2022
Dec. 31, 2021
Business Acquisition [Line Items]      
Goodwill $ 1,075.2   $ 1,002.2
ViaCyte      
Business Acquisition [Line Items]      
Cash and cash equivalents   $ 19.1  
Goodwill   73.0  
Net other assets   6.3  
Total purchase price   $ 315.0  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Net income $ 930.5 $ 851.9 $ 2,503.1 $ 1,572.0
Basic weighted-average common shares outstanding (in shares) 256.5 257.9 255.8 258.7
Effect of potentially dilutive securities:        
Employee stock purchase program (in shares) 0.0 0.0 0.1 0.0
Diluted weighted-average common shares outstanding (in shares) 259.5 259.7 258.7 260.9
Basic net income per common share (in dollars per share) $ 3.63 $ 3.30 $ 9.78 $ 6.08
Diluted net income per common share (in dollars per share) $ 3.59 $ 3.28 $ 9.68 $ 6.03
Stock options        
Effect of potentially dilutive securities:        
Share-based payment arrangements (in shares) 1.4 1.0 1.4 1.1
Restricted stock units (including PSUs)        
Effect of potentially dilutive securities:        
Share-based payment arrangements (in shares) 1.6 0.8 1.4 1.1
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 1.1 0.0 0.7
Unvested restricted stock units (including PSUs)        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 0.2 0.2 0.4
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Additional Information (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash $ 3,500.0 $ 3,500.0 $ 3,300.0
In Process Research and Development | ViaCyte      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Intangible assets 603.6 603.6 $ 400.0
Indefinite-lived intangible assets 216.6    
Impairment of intangible assets   13.0  
Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Remaining milestone payment $ 678.3 $ 678.3  
Level 3 | Minimum | Discount Rate      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Contingent consideration, measurement input (as a percent) 0.052 0.052  
Level 3 | Maximum | Discount Rate      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Contingent consideration, measurement input (as a percent) 0.057 0.057  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Financial instruments carried at fair value (liability positions):    
Long-term contingent consideration $ (127.2) $ (186.5)
Recurring Basis    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 191.6 44.5
Other assets, foreign currency forward contracts 9.1 2.0
Total financial assets 6,429.0 4,254.5
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (0.0) (5.6)
Long-term contingent consideration (127.2) (186.5)
Other long-term liabilities, foreign currency forward contracts (0.0) (2.7)
Total financial liabilities (127.2) (194.8)
Recurring Basis | Level 1    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 0.0 0.0
Other assets, foreign currency forward contracts 0.0 0.0
Total financial assets 3,829.6 3,864.4
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Long-term contingent consideration 0.0 0.0
Other long-term liabilities, foreign currency forward contracts 0.0 0.0
Total financial liabilities 0.0 0.0
Recurring Basis | Level 2    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 191.6 44.5
Other assets, foreign currency forward contracts 9.1 2.0
Total financial assets 2,599.4 390.1
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (0.0) (5.6)
Long-term contingent consideration 0.0 0.0
Other long-term liabilities, foreign currency forward contracts (0.0) (2.7)
Total financial liabilities (0.0) (8.3)
Recurring Basis | Level 3    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 0.0 0.0
Other assets, foreign currency forward contracts 0.0 0.0
Total financial assets 0.0 0.0
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Long-term contingent consideration (127.2) (186.5)
Other long-term liabilities, foreign currency forward contracts 0.0 0.0
Total financial liabilities (127.2) (186.5)
Recurring Basis | Money market funds    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 3,610.9 3,478.1
Recurring Basis | Money market funds | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 3,610.9 3,478.1
Recurring Basis | Money market funds | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Recurring Basis | Money market funds | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Recurring Basis | Time deposits    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 2,000.0 0.0
Recurring Basis | Time deposits | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Recurring Basis | Time deposits | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 2,000.0 0.0
Recurring Basis | Time deposits | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Recurring Basis | Commercial paper    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 18.2 0.0
Marketable securities: 269.1 252.7
Recurring Basis | Commercial paper | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Recurring Basis | Commercial paper | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 18.2 0.0
Marketable securities: 269.1 252.7
Recurring Basis | Commercial paper | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Recurring Basis | Corporate equity securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 122.8 230.9
Recurring Basis | Corporate equity securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 78.2 230.9
Recurring Basis | Corporate equity securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 44.6 0.0
Recurring Basis | Corporate equity securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Recurring Basis | U.S. Treasury securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 130.0 86.4
Recurring Basis | U.S. Treasury securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 130.0 86.4
Recurring Basis | U.S. Treasury securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Recurring Basis | U.S. Treasury securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Recurring Basis | Government-sponsored enterprise securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 10.5 69.0
Recurring Basis | Government-sponsored enterprise securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 10.5 69.0
Recurring Basis | Government-sponsored enterprise securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Recurring Basis | Government-sponsored enterprise securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Recurring Basis | Corporate debt securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 66.8 90.9
Recurring Basis | Corporate debt securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Recurring Basis | Corporate debt securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 66.8 90.9
Recurring Basis | Corporate debt securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: $ 0.0 $ 0.0
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at December 31, 2021     $ 186.5  
Decrease in fair value of contingent payments $ (2.6) $ 1.2 (59.3) $ (1.1)
Balance at September 30, 2022 $ 127.2   $ 127.2  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Summary of cash, cash equivalents and marketable securities          
Cash $ 3,500,000,000   $ 3,500,000,000   $ 3,300,000,000
Net unrealized gains (losses) 16,700,000 $ 46,700,000 (143,100,000) $ 5,000,000.0  
Allowance for credit loss for available-for-sale debt securities 0 $ 0 0 $ 0  
Other Assets          
Summary of cash, cash equivalents and marketable securities          
Equity securities without readily determinable fair value, amount $ 98,600,000   $ 98,600,000    
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Cash equivalents:        
Amortized Cost $ 9,171.5 $ 6,795.0 $ 6,275.7 $ 5,988.2
Total marketable debt securities        
Fair Value 4,105.5 3,977.1    
Corporate equity securities        
Amortized Cost 104.4 69.4    
Gross Unrealized Gains 29.2 167.1    
Gross Unrealized Losses (10.8) (5.6)    
Fair Value 122.8 230.9    
Amortized Cost 584.9 568.9    
Gross Unrealized Gains 29.2 167.1    
Gross Unrealized Losses (14.9) (6.1)    
Fair Value 599.2 729.9    
Cash equivalents:        
Cash equivalents:        
Amortized Cost 5,629.1 3,478.1    
Fair Value 5,629.1 3,478.1    
Total marketable debt securities        
Fair Value 3,629.1 3,478.1    
Cash equivalents: | Money market funds        
Cash equivalents:        
Amortized Cost 3,610.9 3,478.1    
Fair Value 3,610.9 3,478.1    
Cash equivalents: | Time deposits        
Cash equivalents:        
Amortized Cost 2,000.0 0.0    
Fair Value 2,000.0 0.0    
Cash equivalents: | Commercial paper        
Cash equivalents:        
Amortized Cost 18.2 0.0    
Fair Value 18.2 0.0    
Marketable securities        
Total marketable debt securities        
Amortized Cost 480.5 499.5    
Gross Unrealized Gains 0.0 0.0    
Gross Unrealized Losses (4.1) (0.5)    
Fair Value 476.4 499.0    
Marketable securities | U.S. Treasury securities        
Total marketable debt securities        
Amortized Cost 131.7 86.6    
Gross Unrealized Gains 0.0 0.0    
Gross Unrealized Losses (1.7) (0.2)    
Fair Value 130.0 86.4    
Marketable securities | Government-sponsored enterprise securities        
Total marketable debt securities        
Amortized Cost 10.6 69.0    
Gross Unrealized Gains 0.0 0.0    
Gross Unrealized Losses (0.1) 0.0    
Fair Value 10.5 69.0    
Marketable securities | Corporate debt securities        
Total marketable debt securities        
Amortized Cost 67.8 91.1    
Gross Unrealized Gains 0.0 0.0    
Gross Unrealized Losses (1.0) (0.2)    
Fair Value 66.8 90.9    
Marketable securities | Commercial paper        
Total marketable debt securities        
Amortized Cost 270.4 252.8    
Gross Unrealized Gains 0.0 0.0    
Gross Unrealized Losses (1.3) (0.1)    
Fair Value $ 269.1 $ 252.7    
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 4,105.5 $ 3,977.1
Cash and cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Debt securities 3,629.1 3,478.1
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 476.4 $ 499.0
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 4,091.4 $ 3,912.3
Matures after one year through five years 14.1 64.8
Total $ 4,105.5 $ 3,977.1
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance $ 11,933.5 $ 9,196.4 $ 10,100.0 $ 8,686.8
Other comprehensive (loss) income before reclassifications     183.8 49.2
Amounts reclassified from accumulated other comprehensive income (loss)     (102.1) 30.8
Total other comprehensive income 40.1 36.7 81.7 80.0
Ending balance 13,029.6 9,530.8 13,029.6 9,530.8
Foreign Currency Translation Adjustment        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance     (13.6) (15.6)
Other comprehensive (loss) income before reclassifications     (42.8) 3.3
Amounts reclassified from accumulated other comprehensive income (loss)     0.0 0.0
Total other comprehensive income     (42.8) 3.3
Ending balance (56.4) (12.3) (56.4) (12.3)
On Available-For-Sale Debt Securities        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance     (0.5) 0.3
Other comprehensive (loss) income before reclassifications     (3.6) (0.3)
Amounts reclassified from accumulated other comprehensive income (loss)     0.0 0.0
Total other comprehensive income     (3.6) (0.3)
Ending balance (4.1) 0.0 (4.1) 0.0
On Foreign Currency Forward Contracts        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance     30.0 (53.2)
Other comprehensive (loss) income before reclassifications     230.2 46.2
Amounts reclassified from accumulated other comprehensive income (loss)     (102.1) 30.8
Total other comprehensive income     128.1 77.0
Ending balance 158.1 23.8 158.1 23.8
Total        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance 57.5 (25.2) 15.9 (68.5)
Total other comprehensive income 40.1 36.7 81.7 80.0
Ending balance $ 97.6 $ 11.5 $ 97.6 $ 11.5
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging - Additional Information (Details) - Foreign Currency Forward Contracts
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Not Designated as Hedging Instrument  
Derivative [Line Items]  
Notional amount of foreign currency forward contract $ 641.6
Cash Flow Hedging | Minimum  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Maximum  
Derivative [Line Items]  
Derivative term 18 months
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging - Notional Amount (Details) - Foreign Currency Forward Contracts - Designated as Hedging Instruments - Cash Flow Hedging - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 1,667.7 $ 1,892.5
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 1,081.9 1,364.5
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 192.3 89.9
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 183.5 287.7
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 150.8 96.3
Swiss Franc    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 59.2 $ 54.1
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]        
Revenues $ 2,334.3 $ 1,984.1 $ 6,628.0 $ 5,501.8
Other income (expense), net 17.2 42.4 (133.7) (2.2)
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign Currency Forward Contracts | Not designated as hedging instruments        
Derivative Instruments, Gain (Loss) [Line Items]        
Other income (expense), net (22.1) (0.4) (38.9) (9.4)
Product revenues, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Revenues 2,334.3 1,984.1 6,628.0 5,500.8
Product revenues, net | Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign Currency Forward Contracts | Designated as hedging instruments        
Derivative Instruments, Gain (Loss) [Line Items]        
Revenues $ 65.2 $ (5.2) $ 130.3 $ (39.3)
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging - Derivative Fair Value (Details) - Designated as Hedging Instruments - Foreign Currency Forward Contracts - Cash Flow Hedging - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Derivative [Line Items]    
Total assets $ 200.7 $ 46.5
Total liabilities (0.0) (8.3)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Total assets 191.6 44.5
Other assets    
Derivative [Line Items]    
Total assets 9.1 2.0
Other current liabilities    
Derivative [Line Items]    
Total liabilities (0.0) (5.6)
Other long-term liabilities    
Derivative [Line Items]    
Total liabilities $ (0.0) $ (2.7)
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Hedging - Offsetting Derivatives (Details) - Cash Flow Hedging - Designated as Hedging Instruments - Foreign Currency Forward Contracts - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 200.7 $ 46.5
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented 200.7 46.5
Gross Amounts Not Offset (0.0) (8.3)
Legal Offset 200.7 38.2
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (0.0) (8.3)
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented (0.0) (8.3)
Gross Amounts Not Offset 0.0 8.3
Legal Offset $ 0.0 $ 0.0
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 32.2 $ 42.4
Work-in-process 229.3 224.0
Finished goods 126.7 86.7
Total $ 388.2 $ 353.1
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” $ 135.6 $ 103.0 $ 379.8 $ 322.8
Stock-based compensation expense related to inventories 0.3 (0.7) 0.4 (3.8)
Total stock-based compensation expense included in “Total costs and expenses” 135.6 103.0 379.8 322.8
Income tax effect (38.8) (21.6) (101.3) (73.7)
Total stock-based compensation expense, net of tax 96.8 81.4 278.5 249.1
Cost of sales        
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” 2.4 1.6 7.0 4.6
Research and development expenses        
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” 80.0 61.0 229.9 196.4
Selling, general and administrative expenses        
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” 53.2 40.4 142.9 121.8
Restricted stock units (including PSUs)        
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” 130.3 89.5 351.5 279.1
Stock options        
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” 3.1 7.9 14.9 29.6
ESPP share issuances        
Stock-based compensation expense:        
Total stock-based compensation expense included in “Total costs and expenses” $ 1.9 $ 6.3 $ 13.0 $ 17.9
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Nov. 30, 2020
Equity, Class of Treasury Stock [Line Items]            
Value of shares repurchased $ 642,200,000     $ 1,067,200,000    
Share Repurchase Program 2020            
Equity, Class of Treasury Stock [Line Items]            
Number of shares authorized to be repurchased           $ 500,000,000
Shares repurchased (in shares)   2,000,000.0        
Value of shares repurchased   $ 424,900,000        
Share Repurchase Program 2021            
Equity, Class of Treasury Stock [Line Items]            
Number of shares authorized to be repurchased         $ 1,500,000,000  
Shares repurchased (in shares)     0      
Stock repurchase program, remaining amount     $ 499,700,000      
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Income Tax Disclosure [Abstract]          
Income before provision for income taxes $ 1,176.4 $ 1,082.8 $ 3,155.6 $ 1,859.5  
Provision for income taxes $ 245.9 $ 230.9 $ 652.5 $ 287.5  
Effective tax rate 21.00% 21.00% 21.00% 15.00%  
Discrete tax benefit associated with an increase in U.K.'s corporate tax rate       $ 99.7  
Net unrecognized tax benefits which would affect the tax rate if recognized $ 144.9   $ 144.9   $ 129.5
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended
Jul. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2019
Line of Credit Facility [Line Items]        
Indemnification claims   $ 0    
Contingent liabilities   0 $ 0  
Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Line of credit facility additional borrowing capacity $ 500,000,000      
Line of credit facility, maximum borrowing capacity $ 500,000,000 $ 2,000,000,000   $ 500,000,000
Debt covenant, consolidated leverage ratio 3.50      
Debt covenant, increase in consolidated leverage ratio 4.00      
Letters of Credit        
Line of Credit Facility [Line Items]        
Line of credit facility, maximum borrowing capacity $ 100,000,000      
Minimum | Base Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 0.00%      
Minimum | SOFR Loan        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 1.00%      
Maximum | Base Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 0.50%      
Maximum | SOFR Loan        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 1.50%      
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Additional Cash Flow Information (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 9,171.5 $ 6,795.0 $ 6,275.7 $ 5,988.2
Prepaid expenses and other current assets 5.5 5.1 4.5 0.7
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows $ 9,177.0 $ 6,800.1 $ 6,280.2 $ 5,988.9
XML 74 vrtx-20220930_htm.xml IDEA: XBRL DOCUMENT 0000875320 2022-01-01 2022-09-30 0000875320 2022-10-21 0000875320 us-gaap:ProductMember 2022-07-01 2022-09-30 0000875320 us-gaap:ProductMember 2021-07-01 2021-09-30 0000875320 us-gaap:ProductMember 2022-01-01 2022-09-30 0000875320 us-gaap:ProductMember 2021-01-01 2021-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2022-07-01 2022-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2021-07-01 2021-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2022-01-01 2022-09-30 0000875320 vrtx:CollaborativeandRoyaltyMember 2021-01-01 2021-09-30 0000875320 2022-07-01 2022-09-30 0000875320 2021-07-01 2021-09-30 0000875320 2021-01-01 2021-09-30 0000875320 2022-09-30 0000875320 2021-12-31 0000875320 us-gaap:CommonStockMember 2021-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000875320 us-gaap:RetainedEarningsMember 2021-06-30 0000875320 2021-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000875320 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000875320 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000875320 us-gaap:CommonStockMember 2021-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000875320 us-gaap:RetainedEarningsMember 2021-09-30 0000875320 2021-09-30 0000875320 us-gaap:CommonStockMember 2022-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000875320 us-gaap:RetainedEarningsMember 2022-06-30 0000875320 2022-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000875320 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000875320 us-gaap:RetainedEarningsMember 2022-09-30 0000875320 us-gaap:CommonStockMember 2020-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000875320 us-gaap:RetainedEarningsMember 2020-12-31 0000875320 2020-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000875320 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000875320 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000875320 us-gaap:CommonStockMember 2021-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000875320 us-gaap:RetainedEarningsMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000875320 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2022-07-01 2022-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2021-07-01 2021-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2022-01-01 2022-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2021-01-01 2021-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2022-07-01 2022-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2021-07-01 2021-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2022-01-01 2022-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2021-01-01 2021-09-30 0000875320 vrtx:ORKAMBIMember 2022-07-01 2022-09-30 0000875320 vrtx:ORKAMBIMember 2021-07-01 2021-09-30 0000875320 vrtx:ORKAMBIMember 2022-01-01 2022-09-30 0000875320 vrtx:ORKAMBIMember 2021-01-01 2021-09-30 0000875320 vrtx:KalydecoMember 2022-07-01 2022-09-30 0000875320 vrtx:KalydecoMember 2021-07-01 2021-09-30 0000875320 vrtx:KalydecoMember 2022-01-01 2022-09-30 0000875320 vrtx:KalydecoMember 2021-01-01 2021-09-30 0000875320 country:US 2022-07-01 2022-09-30 0000875320 country:US 2021-07-01 2021-09-30 0000875320 country:US 2022-01-01 2022-09-30 0000875320 country:US 2021-01-01 2021-09-30 0000875320 srt:EuropeMember 2022-07-01 2022-09-30 0000875320 srt:EuropeMember 2021-07-01 2021-09-30 0000875320 srt:EuropeMember 2022-01-01 2022-09-30 0000875320 srt:EuropeMember 2021-01-01 2021-09-30 0000875320 vrtx:OtherNonU.S.Member 2022-07-01 2022-09-30 0000875320 vrtx:OtherNonU.S.Member 2021-07-01 2021-09-30 0000875320 vrtx:OtherNonU.S.Member 2022-01-01 2022-09-30 0000875320 vrtx:OtherNonU.S.Member 2021-01-01 2021-09-30 0000875320 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000875320 us-gaap:NonUsMember 2021-07-01 2021-09-30 0000875320 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000875320 us-gaap:NonUsMember 2021-01-01 2021-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRSIPRARJDCAMember 2021-04-01 2021-06-30 0000875320 vrtx:CRSIPRARJDCAMember 2021-07-01 0000875320 vrtx:CRSIPRARJDCAMember vrtx:CRISPRMember 2021-07-01 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-07-01 2022-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-07-01 2021-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember vrtx:CostsAndExpensesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-07-01 2022-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember vrtx:CostsAndExpensesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-07-01 2021-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember vrtx:CostsAndExpensesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember vrtx:CostsAndExpensesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-09-30 0000875320 vrtx:VerveMember 2022-07-01 2022-07-31 0000875320 vrtx:CatalystBiosciencesMember 2022-05-01 2022-05-31 0000875320 vrtx:ViaCyteMember 2022-09-27 2022-09-27 0000875320 vrtx:ViaCyteMember 2022-09-27 0000875320 vrtx:ViaCyteMember us-gaap:InProcessResearchAndDevelopmentMember 2022-09-27 0000875320 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member 2022-09-30 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2022-09-30 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2022-09-30 0000875320 vrtx:ViaCyteMember us-gaap:InProcessResearchAndDevelopmentMember 2022-09-30 0000875320 vrtx:ViaCyteMember us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000875320 vrtx:ViaCyteMember us-gaap:InProcessResearchAndDevelopmentMember 2022-07-01 2022-09-30 0000875320 vrtx:ViaCyteMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember 2022-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2022-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2022-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember 2022-09-30 0000875320 vrtx:MarketableSecuritiesMember 2021-12-31 0000875320 2021-01-01 2021-12-31 0000875320 us-gaap:OtherAssetsMember 2022-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2022-09-30 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0000875320 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0000875320 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0000875320 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0000875320 us-gaap:EmployeeStockMember 2022-07-01 2022-09-30 0000875320 us-gaap:EmployeeStockMember 2021-07-01 2021-09-30 0000875320 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0000875320 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0000875320 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000875320 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000875320 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000875320 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000875320 vrtx:ShareRepurchaseProgram2020Member 2020-11-30 0000875320 vrtx:ShareRepurchaseProgram2020Member 2021-01-01 2021-03-31 0000875320 vrtx:ShareRepurchaseProgram2021Member 2021-06-30 0000875320 vrtx:ShareRepurchaseProgram2021Member 2022-01-01 2022-09-30 0000875320 vrtx:ShareRepurchaseProgram2021Member 2022-09-30 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-31 0000875320 us-gaap:LetterOfCreditMember 2022-07-31 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-01 2022-07-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-01 2022-07-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-09-30 shares iso4217:USD iso4217:USD shares vrtx:segment vrtx:target pure VERTEX PHARMACEUTICALS INC / MA 0000875320 --12-31 2022 Q3 false P1M 10-Q true 2022-09-30 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes Yes Large Accelerated Filer false false false 256691452 2334300000 1984100000 6628000000 5500800000 0 0 0 1000000.0 2334300000 1984100000 6628000000 5501800000 289400000 236500000 797000000.0 656800000 645000000.0 467000000.0 1846200000 1370000000 29000000.0 26700000 92900000 986800000 246800000 198200000 677300000 584900000 -2600000 1200000 -59300000 -1100000 1207600000 929600000 3354100000 3597400000 1126700000 1054500000 3273900000 1904400000 46200000 1100000 58600000 3700000 -13700000 -15200000 -43200000 -46400000 17200000 42400000 -133700000 -2200000 1176400000 1082800000 3155600000 1859500000 245900000 230900000 652500000 287500000 930500000 851900000 2503100000 1572000000 3.63 3.30 9.78 6.08 3.59 3.28 9.68 6.03 256500000 257900000 255800000 258700000 259500000 259700000 258700000 260900000 930500000 851900000 2503100000 1572000000 -600000 -0.0 -3600000 -300000 -16000000.0 -9600000 -34300000 -21200000 58800000 34700000 128100000 77000000.0 -18100000 2000000.0 -42800000 3300000 40100000 36700000 81700000 80000000.0 970600000 888600000 2584800000 1652000000 9171500000 6795000000 599200000 729900000 1385200000 1136800000 388200000 353100000 726900000 545800000 12271000000 9560600000 1118700000 1094100000 1075200000 1002200000 603600000 400000000.0 1162700000 934500000 342700000 330300000 132500000 110800000 16706400000 13432500000 126900000 195000000.0 2264400000 1678600000 218000000.0 268400000 2609300000 2142000000 442300000 509800000 382300000 377400000 127200000 186500000 115700000 116800000 3676800000 3332500000 0 0 0.01 0.01 1000000 1000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 256645737 256645737 254479046 254479046 2600000 2500000 7225500000 6880800000 97600000 15900000 5703900000 3200800000 13029600000 10100000000 16706400000 13432500000 259100000 2600000 7640200000 -25200000 1578800000 9196400000 36700000 36700000 851900000 851900000 3300000 0.0 642200000 642200000 100000 0.0 28600000 28600000 500000 0.0 12900000 12900000 103700000 103700000 256200000 2600000 7086000000 11500000 2430700000 9530800000 256000000.0 2600000 7100000000 57500000 4773400000 11933500000 40100000 40100000 930500000 930500000 200000 0.0 48000000.0 48000000.0 800000 0.0 38200000 38200000 135300000 135300000 256600000 2600000 7225500000 97600000 5703900000 13029600000 259900000 2600000 7894000000 -68500000 858700000 8686800000 80000000.0 80000000.0 1572000000 1572000000 5300000 0.0 1067200000 1067200000 600000 0.0 134200000 134200000 2200000 0.0 66800000 66800000 326600000 326600000 256200000 2600000 7086000000 11500000 2430700000 9530800000 254500000 2500000 6880800000 15900000 3200800000 10100000000 81700000 81700000 2503100000 2503100000 700000 0.0 169900000 169900000 2800000 100000 135200000 135300000 379400000 379400000 256600000 2600000 7225500000 97600000 5703900000 13029600000 2503100000 1572000000 379800000 322800000 109900000 91800000 -59300000 -1100000 -424000000.0 -112700000 -143100000 5000000.0 32800000 -20500000 368800000 231200000 58100000 65800000 41900000 107700000 -39100000 -22000000.0 980300000 254200000 -40700000 -67300000 3051500000 1648500000 417800000 447800000 435900000 452100000 295900000 0 171100000 173200000 47800000 38000000.0 -496700000 -206900000 134700000 67300000 0 1057200000 169900000 134200000 75100000 34600000 0 12600000 2400000 4300000 -107900000 -1141800000 -70000000.0 -8500000 2376900000 291300000 6800100000 5988900000 9177000000 6280200000 41100000 42700000 840100000 381500000 Basis of Presentation and Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of operations. To conform prior periods to current presentation, we reclassified $26.7 million and $986.8 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and nine months ended September 30, 2021, respectively. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted and Issued Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of operations. To conform prior periods to current presentation, we reclassified $26.7 million and $986.8 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and nine months ended September 30, 2021, respectively. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2022 and 2021.</span></div>The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K. 1 26700000 986800000 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> Revenue Recognition <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenues by Product</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues by Geographic Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net product revenues by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had contract liabilities of $119.5 million and $171.7 million as of September 30, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net product revenues by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2010500000 1555800000 5665300000 4004600000 38200000 81400000 145700000 340000000.0 146200000 184500000 399900000 624200000 139400000 162400000 417100000 532000000.0 2334300000 1984100000 6628000000 5500800000 1455600000 1382900000 4238900000 3893200000 730500000 518800000 2018300000 1382700000 148200000 82400000 370800000 224900000 878700000 601200000 2389100000 1607600000 2334300000 1984100000 6628000000 5500800000 119500000 171700000 Acquired In-Process Research and Development and Other Arrangements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $29.0 million and $92.9 million for the three and nine months ended September 30, 2022, respectively, and $26.7 million and $986.8 million, for the three and nine months ended September 30, 2021, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three and nine months ended September 30, 2022 and 2021, or were new or materially revised during the three and nine months ended September 30, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), formerly known as CTX001, for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&amp;R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the A&amp;R JDCA, we lead global development, manufacturing and commercialization of exa-cel, with support from CRISPR. Subject to the terms and conditions of the A&amp;R JDCA, we conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&amp;R JDCA (including exa-cel) throughout the world subject to CRISPR’s reserved right to conduct certain activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the A&amp;R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Acquired in-process research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to exa-cel pursuant to the A&amp;R JDCA began to be allocated 60% to us and 40% to CRISPR, subject to certain adjustments, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&amp;R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three and nine months ended September 30, 2022 and 2021, we recognized the following amounts in total, not including amounts recorded to “Acquired in-process research and development expenses,” related to these agreements:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses incurred under the Original CTX001 JDCA and A&amp;R JDCA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Verve Therapeutics, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into a research collaboration with Verve Therapeutics, Inc. (“Verve”) focused on discovering and developing an in vivo gene-editing program for a liver disease. Under the terms of the agreement, we made a $25.0 million upfront payment to Verve and purchased $35.0 million of Verve’s common stock. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” The investment in Verve’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Catalyst Biosciences, Inc. - Complement 3 Degrader Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, pursuant to an asset purchase agreement, we acquired Catalyst Biosciences, Inc.’s portfolio of protease medicines that target the complement system (the “complement portfolio”) and related intellectual property, including CB 2782-PEG, which is a pre-clinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration. We determined that substantially all the fair value acquired was concentrated in the CB-2782 PEG in-process research and development assets, which did not constitute a business, and for which we determined there was no alternative future use. As a result, we recorded our $60.0 million upfront payment to “Acquired in-process research and development expenses” in the nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”</span></div> 29000000 92900000 26700000 986800000 3 3 410000000 900000000 200000000 0.60 0.40 During the three and nine months ended September 30, 2022 and 2021, we recognized the following amounts in total, not including amounts recorded to “Acquired in-process research and development expenses,” related to these agreements:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses incurred under the Original CTX001 JDCA and A&amp;R JDCA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 98200000 58700000 259800000 147400000 59000000.0 35200000 155900000 79600000 25000000 35000000 60000000 Business Combination<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2022, we acquired all outstanding shares of ViaCyte, Inc. (“ViaCyte”), a privately held biotechnology company primarily focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, in exchange for $315.0 million. ViaCyte’s intellectual property and assembled workforce complement our ongoing programs and have the potential to produce therapies for patients with type 1 diabetes. We accounted for the transaction as a business combination, and allocated the purchase price to the following assets acquired and liabilities assumed:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.297%"><tr><td style="width:1.0%"/><td style="width:64.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.090%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 27, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The “Goodwill” represents the difference between the fair value of the consideration transferred and the fair value of the assets acquired and liabilities assumed. The goodwill is attributable to (i) the technological expertise in cell therapy of ViaCyte’s assembled workforce, (ii) the potential synergies from combining ViaCyte’s technology with our clinical development capabilities and (iii) the potential future benefits for other therapeutic programs that the acquired technology could be used for, but did not meet the definition of an in-process research and development asset. None of the goodwill is expected to be deductible for income tax purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The “Intangible asset” is an in-process research and development asset of $216.6 million related to ViaCyte’s technology and intellectual property associated with stem cell differentiation and manufacturing. The fair value of the intangible asset was determined through a discounted cash flow analysis using the relief from royalty method, which estimated the cost savings associated with owning an asset instead of paying a royalty to the previous owner. The relief from royalty method utilized Level 3 fair value inputs including (i) estimated future product sales, which were calculated using, among other assumptions, an estimated probability of obtaining marketing approval for the asset, (ii) estimated after-tax royalty savings expected from ownership of the asset, and (iii) an appropriate discount and tax rate.</span></div>As of September 30, 2022, our analysis of the fair value of certain assets acquired, including certain tax analyses, related to the ViaCyte business combination is preliminary and will be finalized during the measurement period of up to one year from the acquisition date. The financial results of ViaCyte did not have a material effect on our condensed consolidated statement of operations in the three and nine months ended September 30, 2022 315000000 We accounted for the transaction as a business combination, and allocated the purchase price to the following assets acquired and liabilities assumed:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.297%"><tr><td style="width:1.0%"/><td style="width:64.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.090%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 27, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 19100000 73000000.0 216600000 6300000 315000000.0 0 216600000 Earnings Per Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 930500000 851900000 2503100000 1572000000 256500000 257900000 255800000 258700000 1400000 1000000.0 1400000 1100000 1600000 800000 1400000 1100000 0.0 0.0 100000 0.0 259500000 259700000 258700000 260900000 3.63 3.30 9.78 6.08 3.59 3.28 9.68 6.03 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 1100000 0.0 700000 0.0 200000 200000 400000 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.392%"><tr><td style="width:1.0%"/><td style="width:11.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note G, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,429.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,829.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,599.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,254.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,864.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="48" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note G, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Corporate Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note G, “Marketable Securities and Equity Investments,” for further information on these investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy and other severe neuromuscular diseases, including myotonic dystrophy type 1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.2% and 5.7% as of September 30, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:73.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in fair value of contingent consideration during the nine months ended September 30, 2022 was primarily due to a revision to the scope of certain acquired gene-editing programs in the second quarter of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, we had $603.6 million and $400.0 million, respectively, of in-process research and development intangible assets classified as “Intangible assets” on our condensed consolidated balance sheets. In the third quarter of 2022, we recorded a $216.6 million in-process research and development intangible asset resulting from our acquisition of ViaCyte, which is described in Note D, “Business Combination.” In the nine months ended September 30, 2022, we recorded a $13.0 million impairment of an in-process research and development intangible asset to “Research and development expenses,” due to a decision to revise the scope of certain acquired gene-editing programs.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,429.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,829.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,599.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,254.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,864.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="48" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3500000000 3300000000 3610900000 3610900000 0 0 3478100000 3478100000 0 0 2000000000 0 2000000000 0 0 0 0 0 18200000 0 18200000 0 0 0 0 0 122800000 78200000 44600000 0 230900000 230900000 0 0 130000000.0 130000000.0 0 0 86400000 86400000 0 0 10500000 10500000 0 0 69000000.0 69000000.0 0 0 66800000 0 66800000 0 90900000 0 90900000 0 269100000 0 269100000 0 252700000 0 252700000 0 191600000 0 191600000 0 44500000 0 44500000 0 9100000 0 9100000 0 2000000.0 0 2000000.0 0 6429000000 3829600000 2599400000 0 4254500000 3864400000 390100000 0 0.0 0 0.0 0 5600000 0 5600000 0 127200000 0 0 127200000 186500000 0 0 186500000 0.0 0 0.0 0 2700000 0 2700000 0 127200000 0 0.0 127200000 194800000 0 8300000 186500000 678300000 0.052 0.057 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:73.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 186500000 -59300000 127200000 603600000 400000000 216600000 13000000 Marketable Securities and Equity Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively), is shown below:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:25.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,629.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,629.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,091.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited number of available-for-sale debt securities in insignificant loss positions as of September 30, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three and nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other income (expense), net” in our condensed consolidated statements of operations. During the three and nine months ended September 30, 2022 and 2021, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.5 billion and $3.3 billion of cash as of September 30, 2022 and December 31, 2021, respectively), is shown below:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:25.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,610.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,629.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,629.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,091.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3500000000 3300000000 3610900000 3610900000 3478100000 3478100000 2000000000 2000000000 0 0 18200000 18200000 0 0 5629100000 5629100000 3478100000 3478100000 131700000 0 1700000 130000000.0 86600000 0 200000 86400000 10600000 0 100000 10500000 69000000.0 0 0 69000000.0 67800000 0 1000000.0 66800000 91100000 0 200000 90900000 270400000 0 1300000 269100000 252800000 0 100000 252700000 480500000 0 4100000 476400000 499500000 0 500000 499000000.0 104400000 29200000 10800000 122800000 69400000 167100000 5600000 230900000 584900000 29200000 14900000 599200000 568900000 167100000 6100000 729900000 3629100000 3478100000 476400000 499000000.0 4105500000 3977100000 4091400000 3912300000 14100000 64800000 4105500000 3977100000 0 0 During the three and nine months ended September 30, 2022 and 2021, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 16700000 46700000 -143100000 5000000.0 98600000 Accumulated Other Comprehensive Income (Loss)<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -13600000 -500000 30000000.0 15900000 -42800000 -3600000 230200000 183800000 0 0 102100000 102100000 -42800000 -3600000 128100000 81700000 -56400000 -4100000 158100000 97600000 -15600000 300000 -53200000 -68500000 3300000 -300000 46200000 49200000 0 0 -30800000 -30800000 3300000 -300000 77000000.0 80000000.0 -12300000 0.0 23800000 11500000 Hedging <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMDJkN2U1NjAwYjQ1ODU4YmMyYjVlNzNjN2U0ODJlL3NlYzo0YTAyZDdlNTYwMGI0NTg1OGJjMmI1ZTczYzdlNDgyZV81NS9mcmFnOjhjZDYzNGExOTYwMDRlNzM5YmUyMjljOGVmOTQ3YTEzL3RleHRyZWdpb246OGNkNjM0YTE5NjAwNGU3MzliZTIyOWM4ZWY5NDdhMTNfNDE4_abffbff9-cc01-462d-82b4-c31023fb09e4">one</span> to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2022, all hedges were determined to be highly effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of September 30, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income (expense), net” in our condensed consolidated statements of operations each period. As of September 30, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $641.6 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P18M <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1081900000 1364500000 192300000 89900000 183500000 287700000 150800000 96300000 59200000 54100000 1667700000 1892500000 P1M 641600000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 65200000 -5200000 130300000 -39300000 -22100000 -400000 -38900000 -9400000 2334300000 1984100000 6628000000 5500800000 17200000 42400000 -133700000 -2200000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table> 191600000 0.0 9100000 0.0 200700000 0.0 44500000 5600000 2000000.0 2700000 46500000 8300000 The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 200700000 0 200700000 0.0 200700000 0.0 0 0.0 0.0 0 46500000 0 46500000 8300000 38200000 8300000 0 8300000 8300000 0 Inventories<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 32200000 42400000 229300000 224000000.0 126700000 86700000 388200000 353100000 Stock-based Compensation Expense and Share Repurchase Programs<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022 and 2021, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchase programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, our Board of Directors approved a share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and the first quarter of 2021. During the three months ended March 31, 2021, we repurchased 2.0 million shares of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the nine months ended September 30, 2022, we did not repurchase any shares of our common stock under the 2021 Share Repurchase Program. As of September 30, 2022, a total of $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022 and 2021, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 130300000 89500000 351500000 279100000 3100000 7900000 14900000 29600000 1900000 6300000 13000000.0 17900000 -300000 700000 -400000 3800000 135600000 103000000.0 379800000 322800000 2400000 1600000 7000000.0 4600000 80000000.0 61000000.0 229900000 196400000 53200000 40400000 142900000 121800000 135600000 103000000.0 379800000 322800000 38800000 21600000 101300000 73700000 96800000 81400000 278500000 249100000 500000000 2000000.0 424900000 1500000000 0 499700000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. During the three and nine months ended September 30, 2022 and 2021, we recorded the following provisions for (benefits from) income taxes and effective tax rates as compared to our income before provision for income taxes:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the three and nine months ended September 30, 2022, and the three months ended September 30, 2021, was similar to the U.S. statutory rate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the nine months ended September 30, 2021 was different than the U.S. statutory rate primarily due to a $99.7 million discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2022 and December 31, 2021, we had $144.9 million and $129.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2022, our cash paid for income taxes is substantially increasing due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Jobs Act of 2017, amortize them over a five year period if they are performed in the U.S. and fifteen years if they are performed in foreign jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 (“IRA”) was enacted into law. The IRA includes a 15% corporate alternative minimum tax and a 1% excise tax on share repurchases. We do not expect the IRA to have a significant impact on our consolidated financial statements.</span></div>We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018 in jurisdictions that have a material impact on our consolidated financial statements. During the three and nine months ended September 30, 2022 and 2021, we recorded the following provisions for (benefits from) income taxes and effective tax rates as compared to our income before provision for income taxes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table> 1176400000 1082800000 3155600000 1859500000 245900000 230900000 652500000 287500000 0.21 0.21 0.21 0.15 -99700000 144900000 129500000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Facility</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a SOFR rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of September 30, 2022, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior Credit Facilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, in conjunction with entering our new credit agreement, we terminated the $500.0 million credit agreement we entered into in 2019. In September 2022, a $2.0 billion credit agreement we entered into in 2020 expired in accordance with its terms. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranties and Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note F, “Fair Value Measurements,” there were no material contingent liabilities accrued as of September 30, 2022 or December 31, 2021.</span></div> 500000000 500000000 100000000 0.00000 0.00500 0.01000 0.01500 3.50 4.00 500000000 2000000000 0 0 0 Additional Cash Flow Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,275.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,275.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6795000000 9171500000 5988200000 6275700000 5100000 5500000 700000 4500000 6800100000 9177000000 5988900000 6280200000 EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 299 249 1 false 74 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.vrtx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Recognition Sheet http://www.vrtx.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements Acquired In-Process Research and Development and Other Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Business Combination Sheet http://www.vrtx.com/role/BusinessCombination Business Combination Notes 12 false false R13.htm 0000013 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 13 false false R14.htm 0000014 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 0000015 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments Marketable Securities and Equity Investments Notes 15 false false R16.htm 0000016 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 16 false false R17.htm 0000017 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 17 false false R18.htm 0000018 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 18 false false R19.htm 0000019 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms Stock-based Compensation Expense and Share Repurchase Programs Notes 19 false false R20.htm 0000020 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 0000021 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 0000022 - Disclosure - Additional Cash Flow Information Sheet http://www.vrtx.com/role/AdditionalCashFlowInformation Additional Cash Flow Information Notes 22 false false R23.htm 0000023 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies 23 false false R24.htm 0000024 - Disclosure - Revenue Recognition (Tables) Sheet http://www.vrtx.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.vrtx.com/role/RevenueRecognition 24 false false R25.htm 0000025 - Disclosure - Acquired In-Process Research and Development and Other Arrangements (Tables) Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsTables Acquired In-Process Research and Development and Other Arrangements (Tables) Tables http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements 25 false false R26.htm 0000026 - Disclosure - Business Combination (Tables) Sheet http://www.vrtx.com/role/BusinessCombinationTables Business Combination (Tables) Tables http://www.vrtx.com/role/BusinessCombination 26 false false R27.htm 0000027 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 27 false false R28.htm 0000028 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 28 false false R29.htm 0000029 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments 29 false false R30.htm 0000030 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 30 false false R31.htm 0000031 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 31 false false R32.htm 0000032 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 32 false false R33.htm 0000033 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables Stock-based Compensation Expense and Share Repurchase Programs (Tables) Tables http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms 33 false false R34.htm 0000034 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 34 false false R35.htm 0000035 - Disclosure - Additional Cash Flow Information (Tables) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationTables Additional Cash Flow Information (Tables) Tables http://www.vrtx.com/role/AdditionalCashFlowInformation 35 false false R36.htm 0000036 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies 36 false false R37.htm 0000037 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 37 false false R38.htm 0000038 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 38 false false R39.htm 0000039 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) Details 39 false false R40.htm 0000040 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Collaborative Arrangement Costs (Details) Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails Acquired In-Process Research and Development and Other Arrangements - Collaborative Arrangement Costs (Details) Details 40 false false R41.htm 0000041 - Disclosure - Business Combination - Additional Information (Details) Sheet http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails Business Combination - Additional Information (Details) Details 41 false false R42.htm 0000042 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) Details 42 false false R43.htm 0000043 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 43 false false R44.htm 0000044 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 44 false false R45.htm 0000045 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 45 false false R46.htm 0000046 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 46 false false R47.htm 0000047 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 47 false false R48.htm 0000048 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 48 false false R49.htm 0000049 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 49 false false R50.htm 0000050 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 50 false false R51.htm 0000051 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 51 false false R52.htm 0000052 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 52 false false R53.htm 0000053 - Disclosure - Hedging - Additional Information (Details) Sheet http://www.vrtx.com/role/HedgingAdditionalInformationDetails Hedging - Additional Information (Details) Details 53 false false R54.htm 0000054 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 54 false false R55.htm 0000055 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 55 false false R56.htm 0000056 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 56 false false R57.htm 0000057 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 57 false false R58.htm 0000058 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 58 false false R59.htm 0000059 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Details 59 false false R60.htm 0000060 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Details 60 false false R61.htm 0000061 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxesTables 61 false false R62.htm 0000062 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsandContingencies 62 false false R63.htm 0000063 - Disclosure - Additional Cash Flow Information (Details) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationDetails Additional Cash Flow Information (Details) Details http://www.vrtx.com/role/AdditionalCashFlowInformationTables 63 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:DerivativeTermOfContract - vrtx-20220930.htm 4 vrtx-20220930.htm a2022q310-qexhibit311.htm a2022q310-qexhibit312.htm a2022q310-qexhibit321.htm vrtx-20220930.xsd vrtx-20220930_cal.xml vrtx-20220930_def.xml vrtx-20220930_lab.xml vrtx-20220930_pre.xml vrtx-20220930_g1.gif http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vrtx-20220930.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 299, "dts": { "calculationLink": { "local": [ "vrtx-20220930_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20220930_def.xml" ] }, "inline": { "local": [ "vrtx-20220930.htm" ] }, "labelLink": { "local": [ "vrtx-20220930_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20220930_pre.xml" ] }, "schema": { "local": [ "vrtx-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 449, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 7 }, "keyCustom": 18, "keyStandard": 231, "memberCustom": 16, "memberStandard": 54, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://www.vrtx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Revenue Recognition", "role": "http://www.vrtx.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements", "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements", "shortName": "Acquired In-Process Research and Development and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Business Combination", "role": "http://www.vrtx.com/role/BusinessCombination", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Earnings Per Share", "role": "http://www.vrtx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Fair Value Measurements", "role": "http://www.vrtx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Marketable Securities and Equity Investments", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments", "shortName": "Marketable Securities and Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Hedging", "role": "http://www.vrtx.com/role/Hedging", "shortName": "Hedging", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Inventories", "role": "http://www.vrtx.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income Taxes", "role": "http://www.vrtx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Commitments and Contingencies", "role": "http://www.vrtx.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Additional Cash Flow Information", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformation", "shortName": "Additional Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Basis of Presentation and Accounting Policies (Policies)", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.vrtx.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Acquired In-Process Research and Development and Other Arrangements (Tables)", "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsTables", "shortName": "Acquired In-Process Research and Development and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Business Combination (Tables)", "role": "http://www.vrtx.com/role/BusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.vrtx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Marketable Securities and Equity Investments (Tables)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables", "shortName": "Marketable Securities and Equity Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Hedging (Tables)", "role": "http://www.vrtx.com/role/HedgingTables", "shortName": "Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Inventories (Tables)", "role": "http://www.vrtx.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Income Taxes (Tables)", "role": "http://www.vrtx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Additional Cash Flow Information (Tables)", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationTables", "shortName": "Additional Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Basis of Presentation and Accounting Policies (Details)", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "shortName": "Basis of Presentation and Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "ifb1812a1d0bf4eb89b34bb303f8cd96c_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Revenue Recognition - Additional Information (Details)", "role": "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)", "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "shortName": "Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i4ccd9216e1fd4f598e22dacf7f1fce4b_D20220701-20220731", "decimals": "-5", "lang": "en-US", "name": "vrtx:CollaborativeArrangementUpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i8baee730a8ce4291b4f2b1e3e9e97684_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Collaborative Arrangement Costs (Details)", "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails", "shortName": "Acquired In-Process Research and Development and Other Arrangements - Collaborative Arrangement Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i8baee730a8ce4291b4f2b1e3e9e97684_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i7e7bc2c30fe04365b2d88b69df2d013e_D20220927-20220927", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Business Combination - Additional Information (Details)", "role": "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "shortName": "Business Combination - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i7e7bc2c30fe04365b2d88b69df2d013e_D20220927-20220927", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i66e2f2177ea1462f89fb21d31c23c713_I20220927", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i05236181fadd45c19333412c46187d62_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i05236181fadd45c19333412c46187d62_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i5be74a4252ca41e9bbc25b957448e2bb_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i8744613dea99463b87dbe98785a94191_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i9c865a94b21841bbb122c985b1d04217_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i9c865a94b21841bbb122c985b1d04217_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i5866675aaa7849758104394770a7c354_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i97d555d3563143649b91d1a98bcada67_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Hedging - Additional Information (Details)", "role": "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "shortName": "Hedging - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i97d555d3563143649b91d1a98bcada67_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i77941e4e3c8b40b39d76a5faf1fc3485_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Hedging - Notional Amount (Details)", "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "shortName": "Hedging - Notional Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i77941e4e3c8b40b39d76a5faf1fc3485_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "idb4fa56da45d45048edce12e50e59e37_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i77941e4e3c8b40b39d76a5faf1fc3485_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Hedging - Derivative Fair Value (Details)", "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "shortName": "Hedging - Derivative Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "ia02c2a706c544c04b8a23b97af7be878_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i77941e4e3c8b40b39d76a5faf1fc3485_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Hedging - Offsetting Derivatives (Details)", "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "shortName": "Hedging - Offsetting Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i77941e4e3c8b40b39d76a5faf1fc3485_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Inventories (Details)", "role": "http://www.vrtx.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i9cf5a6d2f8544f029ba14cce62d65d9c_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i100cef74cf314e93a7e79881a09fa608_I20201130", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Income Taxes (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3638f04b67f24fc48cf804d7fc4a1e34_D20220701-20220930", "decimals": "2", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Additional Cash Flow Information (Details)", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "shortName": "Additional Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i78370b09ed4645ecaa1badcabf2c693d_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i9d627351862a46cfbca4816784244288_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i9d627351862a46cfbca4816784244288_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation and Accounting Policies", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies", "shortName": "Basis of Presentation and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220930.htm", "contextRef": "i3d5bd558893a46ad943ce93b456728b7_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 74, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss Franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British pound sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r47", "r50", "r107", "r108", "r245", "r252", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r227", "r228", "r229", "r230", "r244", "r251", "r292", "r294", "r453", "r454", "r455", "r456", "r457", "r458", "r478", "r517", "r520", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r227", "r228", "r229", "r230", "r244", "r251", "r292", "r294", "r453", "r454", "r455", "r456", "r457", "r458", "r478", "r517", "r520", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r166", "r228", "r229", "r271", "r274", "r480", "r516", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r166", "r228", "r229", "r271", "r274", "r480", "r516", "r518" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r222", "r227", "r228", "r229", "r230", "r244", "r251", "r282", "r292", "r294", "r322", "r323", "r324", "r453", "r454", "r455", "r456", "r457", "r458", "r478", "r517", "r520", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r222", "r227", "r228", "r229", "r230", "r244", "r251", "r282", "r292", "r294", "r322", "r323", "r324", "r453", "r454", "r455", "r456", "r457", "r458", "r478", "r517", "r520", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r49", "r50", "r107", "r108", "r245", "r252" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r109", "r562" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Schedule of Additional Cash Flow Information" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r167", "r168", "r271", "r275", "r519", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r560", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r167", "r168", "r271", "r275", "r519", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r170", "r171" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r61", "r68", "r69", "r70", "r71", "r388" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "verboseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r54", "r55", "r56", "r61", "r68", "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "On Available-For-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r58", "r60", "r61", "r505", "r525", "r526" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r68", "r69", "r431", "r432", "r433", "r434", "r435", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r57", "r61", "r68", "r69", "r70", "r111", "r112", "r113", "r389", "r443", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r53", "r61", "r68", "r69", "r70", "r389", "r432", "r433", "r434", "r435", "r437" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment", "verboseLabel": "Foreign Currency Forward Contract" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Additional Cash Flow Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r111", "r112", "r113", "r333", "r334", "r335", "r415" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r296", "r336", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r327" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense included in \u201cTotal costs and expenses\u201d" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "totalLabel": "Total stock-based compensation expense, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r375", "r376", "r377", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Asset acquisition, consideration transferred" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r103", "r155", "r158", "r164", "r190", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r386", "r390", "r429", "r444", "r446", "r486", "r503" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r28", "r103", "r190", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r386", "r390", "r429", "r444", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r419" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (asset positions):" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r178" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r179" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r175", "r197" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Total marketable debt securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r180", "r182", "r501" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Matures after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r180", "r181", "r500" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Matures within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r173", "r176", "r197", "r488" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Total", "verboseLabel": "Debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r400", "r404" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r291", "r293", "r363" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r291", "r293", "r359", "r360", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected to be tax deductible" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r366", "r367", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r96", "r373" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "netLabel": "Decrease in fair value of contingent consideration", "terseLabel": "Decrease in fair value of contingent payments", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r365", "r368", "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at September 30, 2022", "periodStartLabel": "Balance at December 31, 2021" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input (as a percent)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r365", "r369" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "negatedLabel": "Long-term contingent consideration", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r364", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r361" ], "calculation": { "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r361" ], "calculation": { "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Intangible asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r361" ], "calculation": { "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r8", "r446", "r528", "r529" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r8", "r99" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Amortized Cost" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents:", "verboseLabel": "Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash equivalents:", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable Securities and Equity Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r101" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r430" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "verboseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r380", "r381", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Acquired In-Process Research and Development and Other Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r283", "r424" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r35", "r489", "r508" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r226", "r231", "r534" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r111", "r112", "r415" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 256,645,737 and 254,479,046 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67", "r75", "r494", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r74", "r82", "r493", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r260", "r261", "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r283", "r290", "r527" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r78", "r480" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r77" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r177", "r197", "r200", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss for available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r153" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r38", "r52", "r402" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "negatedTerseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r42", "r46" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Legal Offset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r40", "r41", "r46" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedTerseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r39", "r45", "r50", "r428" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "totalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset current, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Other assets, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r37", "r50", "r51", "r402", "r460" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Gross Amounts Recognized", "verboseLabel": "Total assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r37", "r50", "r51", "r402", "r460" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "negatedLabel": "Total liabilities", "negatedTerseLabel": "Gross Amounts Recognized" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r50", "r401", "r403", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r414", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r398", "r401", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r398", "r401", "r406", "r407", "r408", "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r39", "r45", "r50", "r428" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedTerseLabel": "Other current liabilities, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedTerseLabel": "Other long-term liabilities, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r38", "r48", "r52", "r402" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "terseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r42", "r46" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "negatedTotalLabel": "Legal Offset" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r40", "r41", "r46" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "terseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of foreign currency forward contract" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r393", "r395", "r396", "r398", "r399", "r405", "r406", "r409", "r410", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments", "verboseLabel": "Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r299", "r300", "r329", "r330", "r331", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense and Share Repurchase Programs" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r116", "r117", "r118", "r119", "r120", "r125", "r127", "r132", "r133", "r134", "r138", "r139", "r416", "r417", "r495", "r512" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per common share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r116", "r117", "r118", "r119", "r120", "r127", "r132", "r133", "r134", "r138", "r139", "r416", "r417", "r495", "r512" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per common share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r135", "r136", "r137", "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r430" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of changes in exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r327" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP share issuances" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r68", "r69", "r70", "r111", "r112", "r113", "r115", "r121", "r123", "r141", "r191", "r254", "r255", "r333", "r334", "r335", "r350", "r351", "r415", "r431", "r432", "r433", "r434", "r435", "r437", "r443", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r4", "r12", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Fair Value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r189", "r513" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Gains (losses) on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r185", "r502", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "verboseLabel": "Equity securities without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r419", "r420", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r246", "r248", "r249", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r420", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r419", "r420", "r422", "r423", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r246", "r283", "r284", "r289", "r290", "r420", "r450" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r246", "r248", "r249", "r283", "r284", "r289", "r290", "r420", "r451" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r246", "r248", "r249", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r420", "r452" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r246", "r248", "r249", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r424", "r426" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r439" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r440", "r442" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r183", "r184", "r186", "r187", "r188", "r192", "r193", "r194", "r195", "r196", "r198", "r199", "r202", "r203", "r247", "r253", "r414", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r552", "r553", "r554", "r555", "r556", "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTotalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r211", "r213", "r216", "r218", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r211", "r215" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "verboseLabel": "Foreign Currency Forward Contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r9", "r206", "r207", "r208", "r209", "r446", "r485" ], "calculation": { "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r398", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r97", "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r72", "r155", "r157", "r160", "r163", "r165", "r483", "r491", "r498", "r514" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r221", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "verboseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r104", "r345", "r347", "r348", "r352", "r354", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r122", "r123", "r154", "r343", "r353", "r355", "r515" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r340", "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "negatedTerseLabel": "Discrete tax benefit associated with an increase in U.K.'s corporate tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "auth_ref": [ "r128", "r129", "r134" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "terseLabel": "Employee stock purchase program (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r128", "r129", "r130", "r134", "r298" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r212", "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r212", "r217" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-Lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r210", "r214" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r496" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r94", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r21", "r204" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r27", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r23", "r204" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r22", "r204" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r80" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r103", "r159", "r190", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r387", "r390", "r391", "r429", "r444", "r445" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r103", "r190", "r429", "r446", "r487", "r507" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r33", "r103", "r190", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r387", "r390", "r391", "r429", "r444", "r445", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (liability positions):" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r30", "r102" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r490" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities:" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r62", "r65", "r70", "r73", "r98", "r103", "r114", "r116", "r117", "r118", "r119", "r122", "r123", "r131", "r155", "r157", "r160", "r163", "r165", "r190", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r417", "r429", "r492", "r509" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Total product revenues outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instruments", "verboseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r61", "r71" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Schedule of Offsetting Assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Assets [Abstract]", "terseLabel": "Offsetting Derivative Assets [Abstract]" } } }, "localname": "OffsettingDerivativeAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Liabilities [Abstract]", "terseLabel": "Offsetting Derivative Liabilities [Abstract]" } } }, "localname": "OffsettingDerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Schedule of Offsetting Liabilities" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r157", "r160", "r163", "r165" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r439" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r438" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r110", "r124", "r149", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r400", "r411" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets", "verboseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r384", "r385", "r388" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized holding losses on marketable securities, net" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r384", "r385", "r388" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r58" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gains on foreign currency forward contracts, net of tax of $(16.0), $(9.6), $(34.3) and $(21.2), respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r63", "r66", "r384", "r385", "r388" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax", "totalLabel": "Total other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r32", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r83", "r85", "r174" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r86" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payment to acquire ViaCyte, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r250" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r250" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r88", "r332" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r83", "r84", "r174" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturities of available-for-sale debt securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r89", "r91" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenues, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r220", "r441" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r61", "r71" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r339", "r479", "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Collaborative arrangement costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r339" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r8", "r99", "r101", "r484", "r504" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units (including PSUs)", "verboseLabel": "Unvested restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r255", "r446", "r506", "r524", "r526" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r111", "r112", "r113", "r115", "r121", "r123", "r191", "r333", "r334", "r335", "r350", "r351", "r415", "r521", "r523" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r151", "r152", "r156", "r161", "r162", "r166", "r167", "r169", "r270", "r271", "r480" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r273", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r61", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Gross Common Equivalent Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "verboseLabel": "Schedule of Fair Value of Our Contingent Consideration Liabilities" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r359", "r360", "r363" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Schedule of Collaborative Arrangement Costs" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense by Line Item" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Subject to Fair Value Measurements" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r24", "r25", "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories by Type" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedging Instruments" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r295", "r297", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR Loan" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Total stock-based compensation expense included in \u201cTotal costs and expenses\u201d" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r68", "r69", "r70", "r111", "r112", "r113", "r115", "r121", "r123", "r141", "r191", "r254", "r255", "r333", "r334", "r335", "r350", "r351", "r415", "r431", "r432", "r433", "r434", "r435", "r437", "r443", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r111", "r112", "r113", "r141", "r480" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r13", "r14", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r13", "r14", "r254", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "verboseLabel": "Value of shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r103", "r172", "r190", "r429", "r446" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r183", "r184", "r186", "r187", "r188", "r247", "r253", "r414", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r552", "r553", "r554", "r555", "r556", "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r283", "r499" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government-sponsored enterprise securities", "verboseLabel": "Government-sponsored enterprise securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r106", "r283", "r290", "r499" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Net unrealized gains (losses)" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Net unrecognized tax benefits which would affect the tax rate if recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of potentially dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r126", "r134" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r134" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "vrtx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetOtherAssets": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Assets", "terseLabel": "Net other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetOtherAssets", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Remaining Milestone Payment", "label": "Business Combination, Remaining Milestone Payment", "terseLabel": "Remaining milestone payment" } } }, "localname": "BusinessCombinationRemainingMilestonePayment", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CRISPRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR", "label": "CRISPR [Member]", "terseLabel": "CRISPR" } } }, "localname": "CRISPRMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRTherapeuticsAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Therapeutics AG", "label": "CRISPR Therapeutics AG [Member]", "terseLabel": "CRISPR Therapeutics" } } }, "localname": "CRISPRTherapeuticsAGMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRSIPRARJDCAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Amended and restated the Original CTX001 JDCA", "label": "CRSIPR A&R JDCA [Member]", "terseLabel": "CRISPR A&R JDCA" } } }, "localname": "CRSIPRARJDCAMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CatalystBiosciencesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Catalyst Biosciences", "label": "Catalyst Biosciences [Member]", "terseLabel": "Catalyst Biosciences" } } }, "localname": "CatalystBiosciencesMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "label": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "terseLabel": "Allocation of net profits and net losses, percent" } } }, "localname": "CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Collaborative arrangement, development and regulatory potential milestone payments maximum" } } }, "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "terseLabel": "Collaborative arrangement, right to exclusively license, number of targets" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement Up-front License Fee", "label": "Collaborative Arrangement Up-front License Fee", "terseLabel": "Up-front payment" } } }, "localname": "CollaborativeArrangementUpFrontLicenseFee", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant terms of collaboration arrangements, by individual agreement.", "label": "Collaborative Arrangements by Agreement [Axis]", "terseLabel": "Collaborative Arrangements by Agreement [Axis]" } } }, "localname": "CollaborativeArrangementsByAgreementAxis", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeArrangementsByAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements by Agreement [Domain]", "label": "Collaborative Arrangements by Agreement [Domain]", "terseLabel": "Collaborative Arrangements by Agreement [Domain]" } } }, "localname": "CollaborativeArrangementsByAgreementDomain", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeandRoyaltyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative and Royalty [Member]", "label": "Collaborative and Royalty [Member]", "terseLabel": "Other revenues" } } }, "localname": "CollaborativeandRoyaltyMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "vrtx_ContingentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Liabilities", "label": "Contingent Liabilities", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilities", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CostsAndExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs And Expenses", "label": "Costs And Expenses [Member]", "terseLabel": "Total collaborative arrangement costs included in costs and expenses" } } }, "localname": "CostsAndExpensesMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Consolidated Leverage Ratio", "terseLabel": "Debt covenant, consolidated leverage ratio" } } }, "localname": "DebtCovenantConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "terseLabel": "Debt covenant, increase in consolidated leverage ratio" } } }, "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtandEquitySecuritiesCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Cost", "label": "Debt and Equity Securities, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtandEquitySecuritiesCost", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 3.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Fair Value", "label": "Debt and Equity Securities, Fair Value", "terseLabel": "Fair Value" } } }, "localname": "DebtandEquitySecuritiesFairValue", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Gain", "label": "Debt and Equity Securities, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtandEquitySecuritiesUnrealizedGain", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Loss", "label": "Debt and Equity Securities, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "DebtandEquitySecuritiesUnrealizedLoss", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_IndemnificationClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of indemnification claims currently outstanding", "label": "Indemnification Claims", "terseLabel": "Indemnification claims" } } }, "localname": "IndemnificationClaims", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_KalydecoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KALYDECO inventories, net", "label": "KALYDECO [Member]", "terseLabel": "KALYDECO" } } }, "localname": "KalydecoMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increased borrowing capacity available in the future.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_ORKAMBIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ORKAMBI [Member]", "label": "ORKAMBI [Member]", "terseLabel": "ORKAMBI" } } }, "localname": "ORKAMBIMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherNonU.S.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other, Non U.S. [Member]", "label": "Other, Non U.S. [Member]", "terseLabel": "Other" } } }, "localname": "OtherNonU.S.Member", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_PaymentToAcquireCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment To Acquire Common Stock", "label": "Payment To Acquire Common Stock", "terseLabel": "Purchase of common stock" } } }, "localname": "PaymentToAcquireCommonStock", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_PaymentToAcquirePreferredStockAndNotesReceivable": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment To Acquire Preferred Stock and Notes Receivable", "label": "Payment To Acquire Preferred Stock and Notes Receivable", "negatedTerseLabel": "Investment in equity securities and notes receivable" } } }, "localname": "PaymentToAcquirePreferredStockAndNotesReceivable", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ProceedsFromFinanceLeases": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Finance Leases", "label": "Proceeds From Finance Leases", "terseLabel": "Proceeds from finance leases" } } }, "localname": "ProceedsFromFinanceLeases", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_SYMDEKOSYMKEVIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SYMDEKO/SYMKEVI [Member]", "label": "SYMDEKO/SYMKEVI [Member]", "terseLabel": "SYMDEKO/SYMKEVI" } } }, "localname": "SYMDEKOSYMKEVIMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity.", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareBasedCompensationAllocationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share-based Compensation Allocation [Abstract]", "terseLabel": "Stock-based compensation expense:" } } }, "localname": "ShareBasedCompensationAllocationAbstract", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareRepurchaseProgram2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2020", "label": "Share Repurchase Program 2020 [Member]", "terseLabel": "Share Repurchase Program 2020" } } }, "localname": "ShareRepurchaseProgram2020Member", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2021", "label": "Share Repurchase Program 2021 [Member]", "terseLabel": "Share Repurchase Program 2021" } } }, "localname": "ShareRepurchaseProgram2021Member", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_TRIKAFTAKAFTRIOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TRIKAFTA/KAFTRIO [Member]", "label": "TRIKAFTA/KAFTRIO [Member]", "terseLabel": "TRIKAFTA/KAFTRIO" } } }, "localname": "TRIKAFTAKAFTRIOMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_VerveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verve", "label": "Verve [Member]", "terseLabel": "Verve" } } }, "localname": "VerveMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ViaCyteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ViaCyte", "label": "ViaCyte [Member]", "terseLabel": "ViaCyte" } } }, "localname": "ViaCyteMember", "nsuri": "http://www.vrtx.com/20220930", "presentation": [ "http://www.vrtx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.vrtx.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r358": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(ii)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r547": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r548": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r549": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r551": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r552": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r553": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r554": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r555": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r556": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r557": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r558": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r559": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r560": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r561": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r562": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r563": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r564": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r565": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r566": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r567": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r568": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r569": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r570": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r571": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 82 0000875320-22-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-22-000038-xbrl.zip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�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˜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�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end